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ABSTRACT 6 
Boid Inclusion Body Disease (BIBD) is a potentially fatal disease reported in captive boid 7 
snakes worldwide that is caused by reptarenavirus infection. Although the detection of 8 
intracytoplasmic inclusion bodies (IB) in blood cells serves as the gold standard for the ante 9 
mortem diagnosis of BIBD, the mechanisms underlying IB formation and the pathogenesis of 10 
BIBD are unknown. Knowledge on the reptile immune system is sparse compared to the 11 
mammalian counterpart, and in particular the response towards reptarenavirus infection is 12 
practically unknown. Herein, we investigated a breeding collection of 70 Boa constrictor 13 
snakes for BIBD, reptarenavirus viraemia, anti-reptarenavirus IgM and IgY antibodies, and 14 
population parameters. Using NGS and RT-PCR on pooled blood samples of snakes with and 15 
without BIBD, we could identify three different reptarenavirus S segments in the collection. 16 
The examination of individual samples by RT-PCR indicated that the presence of University 17 
of Giessen virus (UGV)-like S segment strongly correlates with IB formation. We could also 18 
demonstrate a negative correlation between BIBD and the presence of anti-UGV NP IgY 19 
antibodies. Further evidence of an association between antibody response and BIBD is the 20 
finding that the level of anti-reptarenavirus antibodies measured by ELISA was lower in 21 
snakes with BIBD. Furthermore, female snakes had a significantly lower body weight when 22 
they had BIBD. Taken together our findings suggest that the detection of the UGV-/S6-like S 23 
segment and the presence of anti-reptarenavirus IgY antibodies might serve as a prognostic 24 
tool for predicting the development of BIBD.   25 
IMPORTANCE 26 
Boid Inclusion Body Disease (BIBD) is a transmissible viral disease of captive snakes and 27 
causes severe losses in collections worldwide. BIBD is caused by reptarenavirus infection, 28 
which can persist over several years without overt signs. The pathogenesis of BIBD is largely 29 
unknown and anecdotal evidence links BIBD with the occurrence of bacterial infections and 30 
neoplasms, indicating potential immunosuppression. Herein we studied a collection of 70 boa 31 
constrictors for BIBD, reptarenavirus viraemia and antibodies against reptarenaviruses, and 32 
correlated the findings with other parameters. Our results show that University of Giessen 33 
virus-like S segment significantly associates with BIBD. They also suggest that the antibody 34 
response against reptarenaviruses among snakes with BIBD is at a lower level than in snakes 35 
without BIBD. While these findings indicate that the anti-reptarenavirus antibody response 36 
per cannot serve as a diagnostic tool for BIBD, they provide evidence supporting 37 
reptarenavirus infection-induced immunosuppression. 38 
  39 
INTRODUCTION 40 
Boid inclusion body disease (BIBD) is a widespread disease of captive boid snakes known 41 
since the 1970s (1–3). The disease is characterised by the presence of eosinophilic and 42 
electron-dense intracytoplasmic inclusion bodies (IBs) in most cell types of affected snakes 43 
(1–3). In the early 2010s, we and others identified arenaviruses as the most likely causative 44 
agents of BIBD, by demonstrating that the IBs consist mainly of arenavirus nucleoprotein (4–45 
7). The causative link was later confirmed by experimental infection of boas and pythons with 46 
reptarenavirus isolates (8). The family Arenaviridae in the order Bunyavirales currently 47 
comprises four genera: Mammarenavirus, Reptarenavirus, Hartmanivirus, and Antennavirus 48 
(9). The arenaviruses found in snakes with BIBD belong to the genera Reptarenavirus and 49 
Hartmanivirus (9).  50 
The genome of reptarenaviruses is a bi-segmented single-stranded negative-sense RNA 51 
with ambisense coding strategy. The small (S) segment encodes the nucleoprotein (NP) and 52 
the glycoprotein precursor (GPC), while the matrix protein (ZP) and the RNA-dependent 53 
RNA polymerase (RdRp) are encoded by the large (L) segment (10). The genome of 54 
hartmaniviruses is similar, except that it lacks the ZP (10). Snakes with BIBD are commonly 55 
co-infected with several reptarenaviruses, and, curiously, they often harbour more L than S 56 
segments (1, 11, 12). The co-existence of multiple segments in an infected snake likely allows 57 
re-assortment of L and S segments (12). The genetic variation between the known 58 
reptarenaviruses is tremendous and up to now L segments of approximately 30 different 59 
reptarenavirus species are known (1, 10–12). The genetic dissimilarity significantly hampers 60 
the development of sensitive “pan-reptarenavirus” RT-PCR tools. Therefore, since the IBs 61 
occur in blood cells including erythrocytes, IB detection in blood smears represents the 62 
current gold standard for ante mortem BIBD diagnosis (3, 13). However, the presence of IBs 63 
does not associate with pathological changes or clinical signs, and thus snakes with 64 
reptarenavirus infection can remain clinically healthy for a long time (4, 8). Subclinical 65 
infections together with horizontal and vertical transmission of reptarenaviruses (1, 12) are 66 
the likely reasons behind reptarenavirus co-infections being rather a rule than an exception in 67 
snakes with BIBD. 68 
Despite the above facts, BIBD appears to be ultimately lethal (1–3). Clinical features 69 
observed in snakes with BIBD include neurological signs, regurgitation, anorexia, pneumonia, 70 
stomatitis, and lymphoproliferative disorders (2, 13, 14). The pathogenesis is poorly 71 
understood, however, the fact that bacterial infections and/or neoplastic processes are 72 
common in snakes with BIBD suggests that the disease is associated with immunosuppression 73 
(2–4). Lymphocytic choriomeningitis virus (LCMV), the prototype arenavirus (genus 74 
Mammarenavirus), induces immunosuppression by inhibition of type I interferon (IFN-I) 75 
production (15–17). The underlying mechanism is prevention of the RIG-I(retinoic acid 76 
inducible gene-I)/MAVS(mitochondrial antiviral signaling) pathway by the NP of LCMV (10, 77 
17). The IFN-I production is further inhibited by the ZP of LCMV, which enters the nucleus 78 
and induces re-localisation of promyelocytic leukemia (PML) bodies to the cytoplasm (10, 18, 79 
19). Intriguingly, PML bodies contribute to tumour suppression which is hampered by their 80 
cytoplasmic localisation (20), thus the ZP of reptarenaviruses could promote tumourigenesis 81 
by such a mechanism. Additionally, the ZP of New World arenaviruses prevents the type I 82 
IFN response by binding to RIG-I (17). 83 
Currently, not much is known about the immune response of snakes to reptarenaviruses. In 84 
fact, the knowledge of the reptile immune response in general is scarce, mainly relying on 85 
individual studies undertaken on different species (21). It has been shown that like all 86 
vertebrates, reptiles mount an innate and adaptive immune response, comprising both humoral 87 
and cell-mediated factors (21, 22). Like in mammals, the humoral branch of the reptile innate 88 
immune system relies heavily on antimicrobial peptides and proteins as well as the 89 
complement pathway (21). Reptiles have equivalents of interleukins (IL), IFNs and Toll-like 90 
receptors and can therefore coordinate their immune response, however, in vitro studies show 91 
the reptile system to be temperature and hormone dependent (21, 23–28). Also, in contrast to 92 
mammals with their cytokine-mediated development of fever, snakes are poikilotherm and 93 
thus increase their body temperature behaviourally by exposing themselves to higher 94 
environmental temperatures as demonstrated by stimulation with bacterial LPS or infection 95 
with gram-negative bacteria (21, 29, 30).  96 
The adaptive immune response of both mammals and reptiles has a cell-mediated and a 97 
humoral component. The former is based on T cells, and in reptiles their proliferation depends 98 
on the seasonal cycle (31–33). Females show a stronger cell-mediated immunity than males in 99 
both mammals and reptiles (21, 34–36), and in the latter T cell proliferation is stronger in 100 
non-gravid than in gravid animals (21, 36). In vertebrates, including reptiles, the 101 
immunoglobulins (Ig) orchestrate the humoral branch of the adaptive immune system. 102 
Reptiles produce Igs of three classes, IgY, IgM and IgD; the leopard gecko (Eublepharis 103 
macularius), for example, also produces IgA (21, 37). The reptile IgM is considered as 104 
equivalent to IgM of other vertebrates, and IgY corresponds to mammalian IgG (22, 38); the 105 
molecular features are similar. Depending on the snake species IgY may occur in three 106 
isotypes, a, b, and c. According to sequence analysis, the IgY isotypes of boid snakes differ 107 
from those of other snake species but show structural similarity to mammalian IgG in that the 108 
heavy and light chains are covalently bound (37). In both reptiles and mammals exposure to 109 
an infectious agent (or other foreign antigen) triggers IgM production approximately within a 110 
week (21). In mammals IgM appears around 10 days (21) and peaks around 10-14 days post 111 
exposure. In reptiles, serum IgM levels reach the peak much later, up to 8 weeks post 112 
exposure, indicating differences in the maturation of the adaptive immune response compared 113 
to mammals (14, 21). Depending on the species studied and the antigens used, the IgM 114 
response in reptiles can last up to 34 weeks after exposure (21), whereas the IgY response 115 
appears around 31 days post exposure and can last for many years, similar to the mammalian 116 
IgG response (39). 117 
Overall, in comparison to mammals, the reptile antibody response is weaker (22) since the 118 
titres do not necessarily increase after a second antigen exposure and there is a lack of affinity 119 
maturation (21, 22). However, studies on colubrid snakes indicated an increase in titres after 120 
repeated antigen exposure (40), and the rapidness of the response indicates immunological 121 
memory (21, 22, 40). Again, the reptile antibody response is affected by environmental and 122 
individual factors such as temperature, season, sex, age, and the neuroendocrine status (14, 123 
22).  124 
We set up this study to assess the antibody response against reptarenaviruses in snakes 125 
with BIBD. Our working hypothesis was that snakes with BIBD would show low anti-126 
reptarenavirus antibody titres, if any. We also wanted to study whether other measurable 127 
parameters, such as the sex, age, and weight of the animals, or the number of reptarenaviruses 128 
infecting an individual snake could be associated with IB formation. To answer these 129 
questions, we studied a cohort (N=70) of snakes in a single breeding collection with 130 
previously confirmed BIBD cases.  131 
  132 
RESULTS 133 
Diagnosis of BIBD based on the cytological examination of blood smears 134 
We based the BIBD diagnosis on the detection of IBs in cells in blood smears stained with 135 
May-Grünwald-Giemsa (7). A similar approach was recently confirmed to correlate well with 136 
immunological staining of peripheral white blood cells (PWBC) for reptarenavirus NP (45). 137 
We could detect IBs (Figure 1) in 34 of the 70 blood smears studied (48.57%; BIBD-positive 138 
snakes; Table 1A). In the remaining 36 snakes (51.43%) the blood cells were free of IBs 139 
(BIBD-negative snakes; Table 1B) (2). At the time of blood sampling, all but the two 140 
debilitated snakes and the animal with cloacal prolapse (animals 1.18, 1.20, 1.29) appeared 141 
clinically healthy. 142 
We examined the animals’ age and weight against the BIBD diagnosis (Table 2). The 143 
average age was 4.6 years (95%CI: 4.26 – 4.99). We did not find statistically significant 144 
differences in age between female and male animals or between BIBD-positive and -negative 145 
animals. However, we found a statistically significant (p<0.01) association between BIBD 146 
and the weight of the female animals: BIBD-positive female animals had significantly lower 147 
body weights (Figure 2); the geometric mean of the weight was 3.077kg for the BIBD-148 
positive female animals and 4.912 kg for the negative ones. The same association was not 149 
significant for male animals (Table 2). Linear regression established that the weight of the 150 
animals was significantly associated with age, sex and BIBD status (Table 3), F(3,63) = 151 
39.67, and they accounted for 63.74% of weight variability. The regression equation is: 152 
Predicted Weight = -0.177 + 0.084 age + 0.255 sex - 0.107 BIBD-positive. 153 
Characterization of the breeding collection’s “reptarenavirome”  154 
We and others have previously reported that snakes with BIBD often harbour several 155 
reptarenavirus L and S segments; usually, more L than S segments are found in each snake (1, 156 
11, 12). To study whether the BIBD-negative snakes would also be free of reptarenavirus 157 
infection, we performed a meta-transcriptomic analysis of pooled blood samples (one pool 158 
from three snakes without evidence of IBs in blood cells, the other from three snakes with a 159 
high number of IBs in blood cells). From the reads acquired by NGS of the BIBD-positive 160 
blood pool we could assemble five reptarenavirus L segments and one S segment, as well as 161 
two pairs of hartmanivirus L and S segments (10). To our surprise, we could not assemble any 162 
full-length L or S segments from the reads acquired from the BIBD-negative blood pool. 163 
However, using a mapping approach we identified some reads matching the L and S segments 164 
assembled from the data of the BIBD-positive blood pool. We then decided to screen a further 165 
three pools of three blood samples by RT-PCR, using virus-specific primers from our earlier 166 
study (1), one pool from BIBD-negative snakes, two from BIBD-positive snakes. We found 167 
the S segments of UGV-2, S5-like, and TSMV-2 to be present in the positive pools, while the 168 
negative pool was only positive for the latter two. The L segment profiles of the pools seemed 169 
variable.  170 
We analysed the population parameters against the RT-PCR test results for associations 171 
with the detection of hartmaniviruses (OScV-1 and -2). OScV-1 detection did not 172 
significantly associate with any of the population parameters, while OScV-2 detection 173 
positively associated with age. The average age of animals without OScV-2 infection was 174 
4.28 years (n=50, 95%CI: 3.895 – 4.665), whereas it was 5.647 (n=17, 95%CI: 40260 – 175 
4.994) for OScV-2 positive snakes (t=-3.498, df: 65, p<0.05). None of the other population 176 
parameters showed any associations with OScV-2 after controlling for age. OScV-1 and -2 177 
detection showed poor to slight agreement with the other tests (Cohen’s kappa < 0.2).  178 
Detection of reptarenavirus S segments in individual samples by RT-PCRs 179 
Reptarenaviruses require both segments to make infectious particles; therefore, we applied 180 
specific RT-PCR for the above identified three S segments to all animals to recognise the 181 
reptarenavirus infected, viraemic snakes. Of the 70 animals tested, we found 66 (94.3%) to 182 
exhibit reptarenavirus viraemia. Thirty snakes (42.9%) carried all three S segments examined 183 
(UGV-/S6-like, S5-like, and TSMV-2), and 32 (45.7%) carried two S segments. Of these, 21 184 
snakes (30%) showed a combination of the S5-like and TSMV-2 S segments, nine snakes 185 
(12.9%) had the UGV-/S6-like and S5-like S segments, and two snakes (2.9%) had the UGV-186 
/S6-like and TSMV-2 S segments. Of the four snakes with a single S segment, we found the 187 
UGV-/S6-like S segment in two, and the S5-like and TSMV-2 S segment in one snake each. 188 
The results are presented in detail in Table 1 and are summarised in Table 4.  189 
We confirmed reptarenavirus viraemia in all BIBD-positive animals, and the majority 190 
(23/34; 67.65%) of these snakes carried all three S segments examined (UGV-/S6-like, S5-191 
like, TSMV-2). Nine BIBD-positive snakes (26.47%) carried two S segments, and we 192 
detected only the UGV-/S6-like S segment in the remaining two animals (5.88%; animals 193 
1.07 and 1.23) (Tables 1 and 4). The UGV-like S segment was present in BIBD-positive 194 
animals. 195 
In BIBD-negative snakes (N=36), we found all three viral S segments in seven snakes 196 
(19.4%), whereas 23 animals (63.9%) carried two S segments, and two snakes (5.56%) had a 197 
single S segment, one had the S5-like (animal 2.19) and the other the TSMV-2 (animal 2.22) 198 
S segment. Four snakes (11.1%) were negative for each S segment and deemed to be 199 
reptarenavirus-free (Tables 1 and 4).  200 
Substantial agreement was identified between BIBD+ status and UGV-/S6-like S segment 201 
RT-PCR results (Cohen’s κ=0.6878). The agreement of the remaining RT-PCR tests with 202 
BIBD is slight (S5-like κ= 0.1327, TMSV-2 κ=0.1254, any segment detection κ=0.183, Table 203 
4). Sensitivity and specificity calculations are included in Table 4, though the study was not 204 
designed for such calculations.  205 
We examined the associations of the RT-PCR results with population parameters (Table 206 
5). Female animals positive for the UGV-/S6-like S segment, as expected given the test 207 
agreement with the presence of IB, have a significantly lower body weight (t=2.99624882, 208 
df=34, p<0.05). For male animals the difference in weight is not significant. There is no 209 
significant difference in the age of UGV-/S6-like S segment RT-PCR-positive and -negative 210 
animals or in their sex distribution. Multiple linear regression established that the age, sex and 211 
a positive UGV-/S6-like S segment RT-PCR result are significantly associated with the 212 
weight of the animals, F (3,63) = 36.98, and they accounted for 62.06% of weight variability. 213 
The regression equation is: Predicted Weight = -0.287 + 0.089 age + 0.235 sex - 0.086 UGV-214 
/S6-like indicating that the weight of UGV-/S6-like positive animals is lower than the weight 215 
of negative snakes after controlling for age and sex.  216 
There is no significant difference in the age of S5-like S segment RT-PCR-positive and -217 
negative animals but there are significantly more male positive animals (χ2=5.8019, p<0.05). 218 
The animals’ weight is not significantly associated with a positive S5-like S segment RT-PCR 219 
result after controlling for sex and age. There is no significant difference in the age of TMSV-220 
2 S segment RT-PCR-positive and -negative animals. There are though significantly more 221 
male animals positive for the TMSV-2 S segment (χ2=4.435, p<0.05). The animals’ weight is 222 
not significantly associated with a positive TMSV-2 S segment RT-PCR result after 223 
controlling for sex and age. 224 
Univariate analysis indicated that the number of S segments detected is not significantly 225 
associated with the age of the animals (ANOVA: F(6,66)=1.17, p=0.333). Male animals had 226 
significantly more S segments (mean = 2.559 [95%CI: 2.236 – 2.755]) than female animals 227 
(mean = 1.972 [95%CI:1.664 – 2.280]), (p<0.01). Linear regression indicates that the number 228 
of segments is negatively associated with the weight of the animals (F(1,68)=8.83, R
2
 = 229 
0.103, Predicted weight = 0.696 - 0.106 number of segments, p<0.01). When the confounding 230 
effect of sex was examined by stratifying for sex, no significant association was identified 231 
between the number of S segments and the animals’ weight. There is a positive association 232 
between the number of segments and the detection of IB in blood cells. The mean number of 233 
segments for BIBD-positive animals is 2.618 (95%CI: 2.407 – 2.828) and for BIBD-negative 234 
animals 1.917 (95%CI: 1.632 – 2.201) (p<0.001). 235 
Antibody response against reptarenavirus NP 236 
So far, not much is known about the antibody response against reptarenaviruses in snakes. 237 
In our first report on identification of reptarenaviruses in snakes with BIBD, we used an 238 
indirect ELISA to indicate that there might be antibodies in some snakes with BIBD (7). In a 239 
more recent study, we generated tools for the detection of IgM and IgY class antibodies in 240 
boas, and, using immunofluorescence and western blot, demonstrated that some BIBD-241 
positive snakes have antibodies against reptarenavirus NP (14).  242 
Antibody detection by western blot (WB)  243 
We studied the plasma samples of the entire collection using WB as the detection tool, and 244 
used concentrated UGV-1 virions as the antigen. The main protein component of the virions 245 
is NP, which is why we interpret the signals as anti-NP IgY and IgM. The signal intensities 246 
varied and we applied the following grading: negative (–), weakly positive (+), moderately 247 
positive (++), and strongly positive (+++); the WB result for each snake is included in Table 248 
1. Among the 34 BIBD-positive snakes, we found five (14.7%) negative for both anti-NP IgY 249 
and IgM, whereas 20 snakes (58.8%) had both anti-NP IgM and IgY antibodies, and nine 250 
(26.5%) had either anti-NP IgY (N=4) or IgM (N=5). Ten snakes were anti-NP IgY-negative 251 
and nine were anti-NP IgM-negative. The 36 BIBD-negative snakes included 22 (61.1%) anti-252 
NP IgY- and IgM-positive snakes, eight (22.2%) were positive for either anti-NP IgY (N=3) 253 
or IgM (N=5), six (16.7%) were negative for both. Eleven snakes were anti-NP IgY-negative 254 
and nine anti-NP IgM negative. Within the entire collection 11 snakes were negative for both 255 
anti-NP IgY and IgM antibodies. There are no significant associations of WB results for NP 256 
IgY or IgM and any of the population parameters. 257 
The WB results for anti-NP IgY and IgM in relation to BIBD are summarised in Table 6. 258 
The agreement of the WB results with BIBD is slight for anti-NP IgY (Cohen’s κ=0.0294) 259 
and poor for IgM (κ=0.0000). As for the RT-PCR results we included indicative sensitivity 260 
and specificity calculations. The sensitivity of the IgY WB in detecting BIBD is 70.6% 261 
(95%CI: 59.8% – 81.4%) and the specificity 32.4% (95%CI:21.2% – 64.3%). For IgM, the 262 
WB sensitivity is 73.5% (95%CI:63.0% - 84.0%) and the specificity 26.5% (95%CI:16.0% - 263 
37.0%). We examined the agreement of the BIBD status against the graded WB results using 264 
Cohen’s weighted kappa(κ(w). For anti-NP IgY κ(w) is 0.0119 and for IgM κ(w) is 0.000 265 
indicating slight and poor agreement, respectively. We also examined the agreement between 266 
WB results and RT-PCR results using Cohen’s kappa for binary WB results and weighted 267 
kappa for graded WB results. In all cases the agreement was slight or poor. For anti-NP IgY 268 
WB results in relation to UGV-2 RT-PCR Cohen’s κ = -0.195 and κ(w) = -0.074; in relation 269 
to S5-like PT-PCR Cohen’s κ = 0.024 and κ(w) = 0.008; in relation to SMTV-2 RT-PCR 270 
Cohen’s κ = 0.088 and κ(w) =0.03. For anti-NP IgM WB results in relation to UGV-2 RT-271 
PCR Cohen’s κ = 0.067 and κ(w) = -0.024; in relation to S5-like RT-PCR Cohen’s κ = 0.061 272 
and κ(w) = 0.02; in relation to SMTV-2 RT-PCR Cohen’s κ = 0.069 and κ(w) = 0.024. 273 
Antibody detection by ELISA  274 
Since the quantification of WB results is at best indicative of the antibody titres, we 275 
decided to set up an ELISA test for the detection of anti-reptarenavirus NP antibodies. We 276 
used purified UGV-1, recombinant UHV-1 NP, and the C-terminal portion of UHV-1 NP 277 
(UHV-1 NP-C) as the antigens. 278 
ELISA results as quantitative variables  279 
We examined the ELISA results against the BIBD status and the RT-PCR results using t-280 
test. UGV-1 IgY ELISA OD values were significantly higher for BIBD- (p<0.001) and UGV-281 
2 RT-PCR- (p<0.05) negative animals, whereas UGV-1 IgM ELISA OD values were 282 
significantly higher for BIBD-positive animals (p<0.05). UHV-1 NP IgY ELISA OD values 283 
were significantly higher for BIBD- (p<0.001) and UGV-2 RT-PCR- (p<0.01) negative 284 
animals, UHV-1 NP-C IgY ELISA OD values were significantly higher for BIBD (p<0.01) 285 
and UGV-2 RT-PCR (p<0.01) negative animals, and UHV-1 NP-C IgM ELISA OD values 286 
were significantly higher for BIBD- (p<0.05) and UGV-2 RT-PCR- (p<0.01) negative 287 
animals and for SMTV-2 RT-PCR-positive animals (p<0.05). Table 7 provides the detailed 288 
results of the analysis. 289 
ELISA results for IgY and IgM from all the tests were analysed against population 290 
parameters and the other tests. At univariate level we used Analysis of Variance (ANOVA) to 291 
examine associations between age and antibody titres. UGV-1 IgY ELISA titres were the only 292 
ones significantly associated with age (F (6,59)=3.52, p<0.01). Linear regression established 293 
that weight was significantly associated with ELISA titres for UGV-1 IgY and UGV-1 IgM 294 
(Regression equations UGV-1 IgY: F(1.67)=32.4, R
2
=0.326, Predicted UGV-1 IgY = -1.245 295 
+ 1.556 weight; Predicted UGV-1 IgM: F(1.67)=4.9= -0.217 -0.188 weight). There was no 296 
significant association between any of the ELISA test results and the animals’ sex. The results 297 
of the univariate analysis are presented in Table 8. 298 
Using multivariable linear regression, we examined the associations of UGV-1 IgY and 299 
IgM with BIBD, weight and age. We established that both age and BIBD+ status were 300 
significantly associated with UGV-1 IgY antibody titres, F(2,63) = 16.94, and they accounted 301 
for 32.90% of antibody variability (p<0.001). The regression equation is: Predicted UGV- 302 
IgY OD(log10) = -1.147 + 0.181 age - 0.4812 BIBD+. Figure 3A illustrates this association, 303 
with BIBD-negative animals demonstrating higher antibody titres than BIBD-positive ones. A 304 
similar model when fitted for UGV-1 IgM did not provide significant results. We include the 305 
graphic representation (Figure 3B) as the result may indicate an interesting trend of UGV-1 306 
IgM remaining at higher levels for BIBD-positive animals because of continuous exposure 307 
from circulating virus while in BIBD-negative snakes, lack of such exposure may lead to 308 
UGV-1 IgM reduction in older animals. Figure 3 (A-F) demonstrates the association of all the 309 
ELISA test results with age and IB detection. 310 
Multivariable linear regression also established that age, sex and plasma UGV1 IgY were 311 
significantly associated (p<0.0001) with the weight of the animals, F(3,62) =38.24  and they 312 
accounted for 63.22% of weight variability. The regression equation is: Predicted Weight = 313 
0.079 + 0.075 age + 0.195 sex - 0.096 UGV1 IgY OD. Figure 4 demonstrates this association 314 
separately for male and female animals. To establish linearity in this and all previous cases, 315 
we checked the residuals for normalcy using Shapiro-Wilk test and examined a residual 316 
versus fitted values plot. 317 
We then investigated the potential association between the number of S segments found 318 
and the antibody response. Of the 23 BIBD-positive snakes in which all three viral S 319 
segments were detected, six (26.09 %) were positive for anti-UGV IgY and 14 (63.64 %) for 320 
anti-UGV IgM antibodies, four (18.18 %) carried both IgY and IgM, and seven (31.82%) 321 
were negative for either antibodies. Among the nine snakes with two S segments were two 322 
(22.22 %) that exhibited anti-UGV IgY antibodies, and three (33.33 %) were positive for anti-323 
UGV IgM antibodies. The two IgY-positive snakes also carried anti-NP IgM antibodies 324 
(22.22%); six snakes (66.67 %) were negative for either antibodies. Both BIBD-positive 325 
snakes in which only the UGV-/S6-like S segment was detected exhibited an anti-NP IgM 326 
response; one also carried anti-NP IgY antibodies. All seven BIBD-negative animals tested 327 
positive for three viral S segments carried UGV-specific antibodies, five (71.43%) were IgY-328 
positive, and three (42.86 %) IgM-positive, one snake (14.29%) was positive for both Igs. Of 329 
the animals positive for two S segments (n=23), the majority carried IgY (n=14; 60.87%), 330 
nine (39.13%) were IgM-positive, and five (21.74%) were positive for both antibodies; five 331 
animals (21.74%) did not exhibit an antibody response. Both snakes in which a single viral S 332 
segment was detected exhibited both an IgY and an IgM response. Of the four RT-PCR 333 
negative animals, two (50%) showed a combined IgY and IgM response, one only had IgY 334 
antibodies, and one did not exhibit an anti-reptarenavirus response. There is no significant 335 
association between the number of segments and any of the ELISA results. 336 
ELISA cut-off points  337 
The background corrected raw ELISA data with cut-off values are presented in Figure 5. 338 
We tested the BIBD-positive snakes for the presence of anti-UGV-1 IgY and IgM antibodies 339 
and found nine (26.5%) IgY positives and 19 (57.58%) IgM positives of which seven 340 
(21.21%) were also IgY-positive. Thirteen animals (39.39%) did not exhibit any anti-UGV-1 341 
antibodies (Table 9A). Of the 36 BIBD-negative snakes 24 (66.67 %) had anti-UGV-1 IgY 342 
and 16 (44.44%) anti-UGV-1 IgM antibodies, 10 animals (27.78%) showed both IgY and 343 
IgM; six snakes (16.67%) did not exhibit any anti-UGV-1 antibodies (Table 9B). 344 
Within the group of BIBD-positive snakes were six (17.65%) that carried anti-UHV-1-NP 345 
IgY and seven (20.59%) positive for IgM. Four snakes (11.76%) carried both antibodies and 346 
25 (73.53%) did not exhibit any anti-UHV-1 antibodies. The examination of UHV-1-NP 347 
antibodies in the BIBD-negative group identified 17 snakes (47.22%) with IgY and nine 348 
(25%) with IgM antibodies. A combination of IgY and IgM was detected in eight snakes 349 
(22.22%), whereas 18 (50%) were negative for both anti-UHV-1-NP antibodies. Of the 350 
BIBD-positives snakes seven (20.59%) had anti-UHV-1-NP-C IgY and 10 (29.41%) IgM 351 
antibodies. Both antibodies were found in five snakes (14.71%) and 22 (64.71%) were 352 
negative for IgY and IgM. Among the BIBD-negative animals 19 (52.78%) carried IgY and 353 
17 (47.22%) were positive for IgM of which 16 (44.44%) also exhibited an IgY antibody 354 
response; 16 snakes (44.44%) did not carry any anti-UHV-1-NP-C antibodies. 355 
We examined the agreement of the different ELISA tests with the BIBD status using 356 
Cohen’s kappa (Table10). Because significantly more BIBD-positive animals were testing 357 
negative for IgY (above the cut-off point, see Table 1), and because the measured OD values 358 
in ELISA were lower in BIBD-positive than in BIBD-negative animals we calculated the test 359 
agreement, using Cohen’s kappa, considering negative ELISA results equivalent to positive 360 
BIBD ones. We reversed thus the UGV-1 IgY ELISA results (positive to negative) which led 361 
to a moderate agreement with BIBD (κ=0.429). The same applied to UHV-1 NP IgY ELISA 362 
(κ = 0.293) and UHV NP-C IgY (κ=0.319) which showed fair agreement with BIBD. All IgM 363 
ELISA results show slight or poor agreement with BIBD (UGV-1 IgM, κ = 0.131; UHV-1 NP 364 
IgM, κ = -0.045; UHV1 NP-C IgM, κ = -0.179). Results are summarised in Tables 10 and 11 365 
including the agreement between ELISA results and RT-PCR. All results indicate poor to fair 366 
agreement between tests. 95% confidence intervals were calculated for Cohen’s kappa and 367 
further confirm the lack of agreement between tests (44).  368 
Using univariate analysis, we examined the ELISA test results based on the cut-off points 369 
for associations with population parameters. There is no significant association between 370 
animal sex and any of the ELISA results. The presence of UGV-IgY is significantly 371 
associated with weight. The geometric mean (GM) weight of UGV-IgY-positive animals 372 
(n=34) is 3.809 kg (95% CI: 3.159 – 4.594) while for UGV-IgY-negative animals (n=36) the 373 
geometric mean weight is 2.193 kg (95%CI: 1.858 – 2.589kg, p<0.0001). This association 374 
remained significant after stratification for sex for both male and female animals (Male: 375 
UGV-IgY positive animals (n=14) GM=2.448 kg [95%CI: 1.995 – 3.004], UGV-IgY negative 376 
animals (n=20) GM=1.809 kg [95%CI: 1.484 – 2.206], p<0.05; Female: UGV-IgY positive 377 
animals (n=16) GM=5.192  kg [95%CI: 4.283 – 6.293 ], UGV-IgY negative animals (n=20) 378 
GM=2.788  kg [95%CI: 2.167 – 3.588], p<0.001). A significant association was also identified 379 
between UGV-IgY and the animals’ age. UGV-IgY-positive animals are significantly older 380 
than negative animals (p<0.001). The average age is 5.313 years (95%CI: 4.783 – 5.842) and 381 
4 years (95%CI: 3.567 – 4.329) for UGV-IgY positive animals (n=32) and negative animals 382 
(n=35) respectively. After stratifying for sex, the association remained significant for female 383 
animals (UGV1 IgY positive animals (n=20) mean age=5.5 years) [95%CI: 4.865 – 6.135]; 384 
UGV-IgY negative (n=16) mean age=4.063 years [95%CI: 3.568 – 4.557], p<0.005). No 385 
other association was identified between any of the ELISA results based on the cut-off point 386 
and population parameters. All the results are presented in Table 12. 387 
  388 
DISCUSSION 389 
In this study, we investigated the association between BIBD, pathogen detection, 390 
population parameters and serological findings in a cohort of snakes from one breeding 391 
colony. As our previous studies had implied an association between BIBD and low antibody 392 
levels (7, 14), the main focus of this study was on a potential link between anti-reptarenavirus 393 
antibody levels and BIBD. We hypothesised that some reptarenavirus S segments can be 394 
found more frequently in snakes with BIBD, and that healthy and diseased snakes would 395 
show different S segment profiles. We examined a panel of 70 blood samples, evenly 396 
distributed by sex, collected on the same day from the entire animal cohort. Because snakes 397 
are poikilotherm, we considered minimising the environmental influence on the immune 398 
response to be essential. Therefore, the study was restricted to a single breeding colony where 399 
animals are kept under virtually the same husbandry conditions with regards to moisture, 400 
light, feeding regime and temperature, except that male snakes are kept at 2-5 °C lower 401 
temperatures than females to increase reproductive activity.  402 
We started by dividing the sample panel in BIBD positives and negatives based on the 403 
detection of IBs in blood cells, using blood smears stained under quality controlled 404 
conditions. The examination of population parameters in our study did not show an 405 
association of age and the presence of IB, suggesting that the time and duration of the 406 
infection would not be a factor in the development of BIBD, though this is highly speculative 407 
as data on, for example, the introduction of individual animals was not available. Also, a 408 
dependency of sex and BIBD could not be shown, but we could demonstrate a statistically 409 
significant association between BIBD and reduced body weight in female snakes. While this 410 
may reflect the low number of snakes included in the study, it might also be indicative of 411 
metabolic or behavioural changes in the infected snakes. Since reptarenaviral replication is 412 
temperature sensitive (46), one could also speculate reptarenaviruses replicate more 413 
efficiently in female snakes as these are housed at slightly higher temperatures. Further 414 
studies on the optimal reptarenavirus replication temperature would be required to address 415 
this hypothesis.  416 
By NGS and de novo genome assembly, we identified two pairs of hartmanivirus L and S 417 
segments, several reptarenavirus L segments but only a single reptarenavirus S segment 418 
(UGV-like) from the RNA of a BIBD-positive blood pool (10). Interestingly, reads matching 419 
reptarenaviruses were clearly less abundant in the RNA sample extracted from the BIBD-420 
negative blood. This finding could indicate higher replication or more intense viraemia in the 421 
BIBD-positive snakes, however, it could also be explained by unknown factors related to 422 
library preparation. As we aimed to study the immune response using NP as the antigen, we 423 
used the S segment primers of our previous study (1) in RT-PCRs to screen the pools, and 424 
identified two additional S segments (S5-like and TSMV-2) within the pools. Screening of all 425 
individual samples for UGV-like, S5-like, and TSMV-2 S segments by RT-PCR showed that 426 
97.1% of the BIBD-positive snakes carried the UGV-like S-segment. This observation is well 427 
in line with previous studies, in which we (1, 11) and others (12) have observed that UGV-428 
/S6-like S segments are often found in snakes with BIBD. In contrast, we found the UGV-429 
/S6-like S segment only in 27.8% of the BIBD-negative snakes. As the mechanisms behind IB 430 
formation are still unknown, one could speculate that UGV-/S6-like NP would be more prone 431 
to IB formation. However, in our first report on reptarenaviruses in snakes, we purified IBs 432 
from infected cell cultures and used peptide mass fingerprinting to identify the main protein 433 
component as University of Helsinki virus-1 (UHV-1) NP. This finding suggests that IB 434 
formation is similar between different reptarenavirus species (or S segments). Thus one 435 
explanation on why UGV-/S6-like S segments are often found in snakes with BIBD could 436 
instead lie in the GPC that is also carried in the S segment. The origin and reservoir host(s) of 437 
reptarenaviruses remain unknown, however, it seems obvious that UGV-/S6-like GPC allows 438 
the virus to spread efficiently among boas. As IBs are found in various tissues, the UGV-/S6-439 
like GPC could also allow wide tissue tropism. Our findings indicated that detection of UGV-440 
/S6-like S segment had the closest substantial agreement (κ=0.6878) with BIBD. However, 441 
further work will be required to establish the sensitivity and specificity of UGV-/S6-like S 442 
segment detection in BIBD diagnosis.  443 
The reptile immune response is not known in great detail, and its description is often 444 
subjected to a comparison with the mammalian immune system. It is also unclear how much 445 
immune response mechanisms vary within the class Reptilia or even within the clade Ophidia 446 
inside the order Squamata since studies on the immune response of snakes partially report 447 
controversial findings, for instance regarding the increase in titres after repeated antigen 448 
exposure in colubrid snakes (40). Also, different IgY isotypes of certain snake species have 449 
been described (37), and a secretory immunoglobulin has only been found in the bile of the 450 
northwestern garter snake (Thamnophis ordinoides) (47). The fact that we studied samples 451 
collected at a single time point from naturally infected snakes for which the time of infection 452 
was unknown, made the evaluation of antibody response kinetics impossible. However, the 453 
analysis of IgY and IgM antibodies by WB and ELISA showed that the presence of anti-UGV 454 
NP IgY is negatively correlated to the presence of IB and thereby BIBD (Figure 2). Assuming 455 
that there is a correlation between anti-NP and anti-glycoprotein response (since they come 456 
from the same segment), our results would suggest that IgY could provide protective 457 
immunity. Further evidence of a possible association between infection with a virus bearing 458 
UGV-/S6-like S segment and BIBD is the observation that we found a significant positive 459 
association between weight and plasma UGV1 IgY titres. The observed variable occurrence 460 
of IgY and IgM antibodies in individual snakes could be due to the prolonged persistence of 461 
IgM and the variable onset of IgY production (21, 39). Anti-UGV NP IgM antibody titres 462 
showed a trend to lower in the older BIBD-negative snakes, which could reflect exhaustion of 463 
the immune system or a gradual class switch towards IgY. The current knowledge on the role 464 
of IgM and its age dependency in protective immunity in snakes is scarce. Natural antibodies 465 
(NAbs) are thought to compensate the decreasing sensitivity of the adaptive immune system 466 
in ageing snakes (48). Interestingly, NAbs are also suggested to provide protection against 467 
mammarenavirus (LCMV) infection by epitope recognition (49). The timing of infection has 468 
great influence on the immune response, as shown for LCMV, the prototypic arenavirus. 469 
Infection in utero or as a neonate results in chronic infections (1, 50). However, despite the 470 
assumption that persistently infected LCMV carriers can develop a state of tolerance, 471 
accepting the virus as endogenous, and therefore do not respond by antibody production (51), 472 
studies demonstrated an immunological response towards LCMV and concluded that low 473 
antibody levels were due to the formation of immune complexes (52). In addition, several 474 
studies elucidated a dependency of antibody production on different strains of viruses and 475 
mice and a different IgG isotype profile in chronic vs. acute infections of mice (53). These 476 
were attributed to involvement of different T cell populations, and associated with varying 477 
clinical signs (53). Exhaustion of CD4
+
 and CD8
+
 T cells is associated with chronic LCMV 478 
infection in mice, and the functional impairment of CD4
+
 T cells also has a negative impact 479 
on the antibody response (54, 55). The production of antibodies is reduced by exhaustion of 480 
CD4
+
 Tcells but can be reversed by providing virus-specific CD4
+
 T cells from transgenic 481 
mice into chronically infected animals (54). Mice persistently infected with LCMV do not 482 
possess LCMV-specific CD8
+
 T cells (53) and CD4
+
 T cells are absent in transplacentally 483 
infected mice (55). The attenuation of T cell dependent immune functions as well as immune 484 
complex formation support the assumption that animals infected via vertical transmission 485 
show lower antibody levels than horizontally infected animals. It is possible that vertical 486 
transmission also occurs for maternal antibodies in ovoviviparous snakes, such as B. 487 
constrictor. This could theoretically compensate for the embryo’s immunological 488 
incompetence; however, how this aligns with the fact that persistently infected mothers pass 489 
both their reptarena- (1) and hartmaniviruses (10) to the newborn is not clear. Many snakes 490 
examined in the present study are related, as they represent a breeding colony; therefore, it is 491 
not possible to determine how many were horizontally infected. It is tempting to speculate 492 
that the snakes with high antibody titres were horizontally infected, whereas the BIBD-493 
positive animals with low antibody titres were vertically infected. This would tie in with 494 
observations on the prototype arenavirus, LCMV, which leads to reduced levels of IgG2a 495 
subclass in persistently infected mice (53). In addition to the antibody response, 496 
reptarenaviruses can be expected to influence the innate immune system in a manner similar 497 
to that of mammarenaviruses i.e. via inhibition of type I interferon production (10, 17, 18, 498 
56). Indeed, a general reptarenavirus-induced immunosuppression would tie in with the 499 
increased incidence of bacterial infections and/or neoplastic processes in snakes with BIBD 500 
(2–4).  501 
This is to our knowledge the first report to thoroughly assess the adaptive immune 502 
response of boid snakes towards reptarenaviruses. By characterising a single breeding 503 
collection, we could demonstrate that one individual virus, UGV-/S6-like S segment, was 504 
strongly associated with BIBD. Supporting the link between the presence of UGV-/S6-like S 505 
segment and BIBD, we found a negative correlation between BIBD and the presence of anti-506 
UGV NP antibodies.  Future studies, either longitudinal or experimental infection driven, are 507 
needed to understand the kinetics of the antibody response in snakes with reptarenavirus 508 
infection. Our results do, however, suggest that presence/absence of UGV-/S6-like S segment 509 
RNA and presence/absence of anti-UGV NP IgY antibodies could serve to a limited extent in 510 
the ante mortem diagnostics of BIBD. 511 
  512 
MATERIALS AND METHODS 513 
Study cohort and samples, cytological examination 514 
We studied a breeding collection of 70 Boa constrictor snakes comprising 36 female and 515 
34 male adult individuals, aged between two and eight years (Table 1). Husbandry conditions 516 
included humidity of approximately 60% and a season-dependent light regime with 517 
photoperiods of 12-13 hours during warm and 9-10 hours during cold months. Female snakes 518 
were kept at an environmental temperature of 26-33 °C with a drop of 3-4 °C during night, 519 
but not deceeding 24 °C whereas the males were kept at an environmental temperature 520 
approximately 2-5 °C lower than the females with a minimum temperature of 23 °C The 521 
cohort included two debilitated snakes (one male, animal 1.20; one female, animal 1.29) and 522 
one female snake with cloacal prolapse (animal 1.18); the remaining animals were clinically 523 
healthy. In June 2015, one snake from the collection had been euthanised due to clinical signs, 524 
and post mortem examination had confirmed BIBD diagnosis. Subsequent analysis of blood 525 
samples from 14 snakes had revealed the presence of cytoplasmic IBs in blood cells of eight 526 
snakes, confirmed that they also suffered from BIBD. These findings prompted the owner to 527 
have the entire breeding colony tested for BIBD a year later. In July 2016, blood samples 528 
were collected in 1.3 ml K3E EDTA tubes (Sarstedt) by either caudal tail vein venipuncture 529 
or cardiocentesis. All snakes were weighed before bleeding. No ethical permissions were 530 
required for these diagnosis-motivated blood samplings.   531 
Blood samples and smears 532 
Cytological examination of blood smears, which presents the current standard ante mortem 533 
diagnostic tool (3, 41), served to confirm BIBD diagnosis. We prepared two blood smears for 534 
each animal, stained with May-Grünwald-Giemsa, and used light microscopy for IB detection 535 
in blood cells as described (1). From the remaining blood, ca. 1 ml each, we separated plasma 536 
by centrifugation at 1,200 g for 2 min, and stored the cell-enriched blood and plasma at -80 537 
°C. 538 
Next generation sequencing (NGS) 539 
NGS served to identify the “reptarenavirome” of the breeding collection, and to allow the 540 
setting up of virus-specific RT-PCRs for screening of the entire collection. For NGS, we 541 
prepared two pooled samples of cell-enriched blood: 1. three snakes without evidence of 542 
BIBD (no IBs in blood cells), 2. three snakes with confirmed BIBD (abundant IBs in blood 543 
cells), and performed RNA extraction, NGS library preparation, and genome assembly as 544 
described (1, 42). 545 
Reverse transcriptase-polymerase chain reaction (RT-PCR) 546 
We were interested in sequencing the S segments present in the breeding colony, since the 547 
S segment bears the NP which we used as the antigen in the antibody assays. As we only 548 
recovered a single complete reptarenavirus S segment (University of Giessen virus-1, UGV-1, 549 
GenBank accession MH483061) by NGS and de novo assembly (10), we decided to use the 550 
virus-specific primers of our previous study (1) to screen three additional RNA pools 551 
prepared from blood samples by RT-PCR: one BIBD-negative (no evidence of IB in blood 552 
cells) and two BIBD-positive. By this approach, we detected: University of Giessen virus-like 553 
(UGV-2 and UGV-3, primers (1)), S5-like (S5-like, primers (1)), and Tavallinen suomalainen 554 
mies virus-2 (TSMV-2, primers (1)) S segments in the BIBD-positive RNA pools; and S5-like 555 
and TSMV-2 S segments in the BIBD-negative RNA pool. We then used these three primer 556 
pairs to screen blood samples of the entire collection by RT-PCR. Additionally, we screened 557 
the collection by RT-PCR with primers targeting the L segments of two hartmaniviruses 558 
identified by NGS and de novo assembly in the BIBD positive pool, i.e. Old Schoolhouse 559 
viruses 1 and 2 (OScV-1, OScV-2) described in a previous study (10). 560 
We did RNA extractions from cell-enriched EDTA blood (100 µl) as described (1), but 561 
introduced a mechanical homogenization step using a Retsch MM300 TissueLyser 562 
(QIAGEN) for 2 min at highest frequency (30 Hertz). The  563 
following primers were used: UGV-2 and -3 S segment (Fwd 5’-564 
ATAAGGTCAGGGTATAACTTGG-3’ and Rev 5’-565 
GAACTTGGCATAAAAATACAAATGAATG-3’), S5-like S segment (Fwd 5’-566 
GTCAGGATAGAGTCTGGGAGCAT-3’ and Rev 5’-567 
TGAACATTCAGAGGGAATTTGGCATC-3’), TSMV-2 S-segment (Fwd 5’-568 
CAAGTCTGGATAAAGTCTTGGTGCAT-3’ and Rev 5’-569 
GTAATTGATGACGACAATAGGGTCGA-3’), OScV-1 L segment (Fwd 5´- 570 
GCACTAAGTGGATCATCAAC-3´ and Rev 5´- CATGCAAACCTGTTGCTG-3´), and 571 
OScV-2 L segment (Fwd 5´- GCACTAAGTGGATCATCAAC-3´ and Rev 5´-572 
GAACAATGTCATAACTTGCTC-3´); RT-PCR was performed as described (1), the 573 
amplicons analysed by agarose gel electrophoresis, and the bands visualised by GelRed 574 
Nucleic Acid Gel Stain  (BIOTIUM) under UV-light with the UVP BioDoc-It Imaging 575 
System (Thermo Fisher Scientific). The GeneRuler 100 bp DNA ladder (Thermo Fisher 576 
Scientific) served as the marker. 577 
Western blot (WB) 578 
We used UGV-1 virions concentrated by ultracentrifugation through a sucrose cushion, 579 
prepared as described in (7), as the antigen in WB. We did the WBs with plasma samples as 580 
described in  (14), but blocked the nitrocellulose membranes for 3-4 h instead of 30 min at 581 
room temperature. We used snake plasma at 1:200 dilution, and the affinity purified 582 
unlabelled anti-IgM and anti-IgY antibodies (14) at respective dilutions of 1:500 and 1:1000. 583 
We evaluated the results recorded using the Odyssey CLx Infrared Imaging System (LI-COR 584 
Biosciences) as negative (–), weakly positive (+), moderately positive (++), and strongly 585 
positive (+++) according to the signal intensity. 586 
Enzyme-linked immunosorbent assay (ELISA) 587 
We set up an ELISA to measure the IgM and IgY levels in the plasma samples using 588 
concentrated UGV-1 virions (inactivated with 1% Triton X-100 [Fluka BioChemika]), and 589 
recombinant UHV-1 NP and UHV-1 NP-C (described in (43)) as the antigens. We diluted the 590 
antigens (UGV-1 at 1:400, UHV-1 NP and UHV-1 NP-C at 2 g/ml) in 0.05M carbonate 591 
buffer, pH 9.6, and used 100 l/well to coat Nunc Microplate Immuno Polysorp (Thermo 592 
Scientific) plates by overnight incubation on an orbital shaker at 4 °C. After coating, we used 593 
1% BSA in PBS (150 l/well) for blocking (2 h at 37 °C), washed once with TBS-T (TBS + 594 
0.05% Tween-20) prior to incubation (1 h at 37 °C) with the plasma samples diluted (1:200 595 
used for UHV-1 NP-C, and 1:400 for UHV-1 NP and UGV-1) in 0.25% BSA/PBS. After four 596 
TBS-T washes, we incubated (45 min at 37 °C) the plates with 100 l/well of horseradish 597 
peroxidase (HRP) labelled anti-boa IgM or anti-boa IgY antibodies, described in (14), diluted 598 
1:2000 in 0.25% BSA/PBS, washed four times with TBS-T, incubated (20 min at RT) with 599 
TMB Substrate Solution (Thermo Scientific) 100 l/well, terminated the reaction by addition 600 
of 1M H2SO4 50 l/well, and read the results (OD at 450 nm) with a BioTek Synergy HT 601 
Multi-Mode Microplate Reader. 602 
We performed change point analysis utilising the changepoint v.2.2.2 package 603 
(https://rdrr.io/cran/changepoint/) in R to set the cut-off values (separately for IgM and IgY 604 
and for each antigen) for distinguishing positive and negative ELISA results. Briefly, we used 605 
the cpt.meanvar function with the AMOC method on the ELISA data arranged in ascending 606 
order. We set the cut-offs (UHV NP IgY=0.31; UHV NP IgM=0.35; UGV-1 IgY=0.27; UGV-607 
1 IgM=0.48; UHV NP-C IgY=0.47; and UHV NP-C IgM=0.37) just above the detected 608 
change point, so that the value at change point was considered negative.  609 
Statistical analysis 610 
We performed data analysis using Stata Statistical Software: Release 13. College Station, 611 
TX: StataCorp LP. The analysis examined possible associations between test results and 612 
population parameters using univariate and multivariable analysis. For data that were not 613 
normally distributed, we utilised non-parametric tests. Given the nature of the investigation 614 
and the study population, the analysis is predominantly descriptive. Sensitivity and specificity 615 
calculations for the different tests were used as indicative since the study was not designed for 616 
the purpose. Cohen’s kappa (κ) and weighted kappa κ (w) served to examine the agreement 617 
between tests with binary or ordinal data (44).   618 
ACKNOWLEDGEMENTS 619 
The authors are grateful to the snake breeder who provided us with the case material for 620 
the present study. They also thank the laboratory staff of the histology laboratory (Institute for 621 
Veterinary Pathology, Vetsuisse faculty, University of Zürich) for excellent technical support. 622 
The study received financial support from the Schweizerische Vereinigung für Wild-, Zoo-623 
und Heimtiermedizin (SVWZH) and the Academy of Finland (grant numbers 1308613 and 624 
1314119). 625 
 626 
  627 
REFERENCES 628 
1. Keller S, Hetzel U, Sironen T, Korzyukov Y, Vapalahti O, Kipar A, Hepojoki J. 2017. 629 
Co-infecting Reptarenaviruses Can Be Vertically Transmitted in Boa Constrictor. PLoS 630 
Pathog 13:e1006179. 631 
2. Schumacher J, Jacobson ER, Homer BL, Gaskin JM. 1994. Inclusion Body Disease in 632 
Boid Snakes. Journal of Zoo and Wildlife Medicine 25:511–524. 633 
3. l-W C, Jacobson E. 2010. Inclusion Body Disease, A Worldwide Infectious Disease of 634 
Boid Snakes: A Review. Journal of Exotic Pet Medicine 19. 635 
4. Wozniak E, McBride J, DeNardo D, Tarara R, Wong V, Osburn B. 2000. Isolation and 636 
characterization of an antigenically distinct 68-kd protein from nonviral intracytoplasmic 637 
inclusions in Boa constrictors chronically infected with the inclusion body disease virus 638 
(IBDV: Retroviridae). Vet Pathol 37:449–459. 639 
5. Bodewes R, Kik MJL, Raj VS, Schapendonk CME, Haagmans BL, Smits SL, Osterhaus, 640 
A D M E. 2013. Detection of novel divergent arenaviruses in boid snakes with inclusion 641 
body disease in The Netherlands. J Gen Virol 94:1206–1210. 642 
6. Stenglein MD, Sanders C, Kistler AL, Ruby JG, Franco JY, Reavill DR, Dunker F, 643 
Derisi JL. 2012. Identification, characterization, and in vitro culture of highly divergent 644 
arenaviruses from boa constrictors and annulated tree boas: candidate etiological agents 645 
for snake inclusion body disease. MBio 3:e00180-12. 646 
7. Hetzel U, Sironen T, Laurinmaki P, Liljeroos L, Patjas A, Henttonen H, Vaheri A, Artelt 647 
A, Kipar A, Butcher SJ, Vapalahti O, Hepojoki J. 2013. Isolation, identification, and 648 
characterization of novel arenaviruses, the etiological agents of boid inclusion body 649 
disease. J Virol 87:10918–10935. 650 
8. Stenglein MD, Sanchez-Migallon Guzman D, Garcia VE, Layton ML, Hoon-Hanks LL, 651 
Boback SM, Keel MK, Drazenovich T, Hawkins MG, Derisi JL. 2017. Differential 652 
Disease Susceptibilities in Experimentally Reptarenavirus-Infected Boa Constrictors and 653 
Ball Pythons. J Virol 91. 654 
9. Abudurexiti A, Adkins S, Alioto D, Alkhovsky SV, Avšič-Županc T, Ballinger MJ, 655 
Bente DA, Beer M, Bergeron É, Blair CD, Briese T, Buchmeier MJ, Burt FJ, Calisher 656 
CH, Cháng C, Charrel RN, Choi IR, Clegg JCS, de la Torre JC, de Lamballerie X, Dèng 657 
F, Di Serio F, Digiaro M, Drebot MA, Duàn X, Ebihara H, Elbeaino T, Ergünay K, 658 
Fulhorst CF, Garrison AR, Gāo GF, Gonzalez JJ, Groschup MH, Günther S, Haenni AL, 659 
Hall RA, Hepojoki J, Hewson R, Hú Z, Hughes HR, Jonson MG, Junglen S, Klempa B, 660 
Klingström J, Kòu C, Laenen L, Lambert AJ, Langevin SA, Liu D, Lukashevich IS, Luò 661 
T, Lǚ C, Maes P, de Souza WM, Marklewitz M, Martelli GP, Matsuno K, Mielke-Ehret 662 
N, Minutolo M, Mirazimi A, Moming A, Mühlbach HP, Naidu R, Navarro B, Nunes 663 
MRT, Palacios G, Papa A, Pauvolid-Corrêa A, Pawęska JT, Qiáo J, Radoshitzky SR, 664 
Resende RO, Romanowski V, Sall AA, Salvato MS, Sasaya T, Shěn S, Shí X, Shirako Y, 665 
Simmonds P, Sironi M, Song JW, Spengler JR, Stenglein MD, Sū Z, Sūn S, Táng S, 666 
Turina M, Wáng B, Wáng C, Wáng H, Wáng J, Wèi T, Whitfield AE, Zerbini FM, 667 
Zhāng J, Zhāng L, Zhāng Y, Zhang YZ, Zhāng Y, Zhou X, Zhū L, Kuhn JH. Taxonomy 668 
of the order Bunyavirales: update 2019. Arch Virol. 2019 May 7. doi:10.1007/s00705-669 
019-04253-6. [Epub ahead of print] PubMed PMID: 31065850. 670 
10. Hepojoki J, Hepojoki S, Smura T, Szirovicza L, Dervas E, Prahauser B, Nufer L, 671 
Schraner EM, Vapalahti O, Kipar A, Hetzel U. 2018. Characterization of Haartman 672 
Institute snake virus-1 (HISV-1) and HISV-like viruses-The representatives of genus 673 
Hartmanivirus, family Arenaviridae. PLoS Pathog 14:e1007415. 674 
11. Hepojoki J, Salmenpera P, Sironen T, Hetzel U, Korzyukov Y, Kipar A, Vapalahti O. 675 
2015. Arenavirus Coinfections Are Common in Snakes with Boid Inclusion Body 676 
Disease. J Virol 89:8657–8660. 677 
12. Stenglein MD, Jacobson ER, Chang L-W, Sanders C, Hawkins MG, Guzman DS-M, 678 
Drazenovich T, Dunker F, Kamaka EK, Fisher D, Reavill DR, Meola LF, Levens G, 679 
Derisi JL. 2015. Widespread recombination, reassortment, and transmission of 680 
unbalanced compound viral genotypes in natural arenavirus infections. PLoS Pathog 681 
11:e1004900. 682 
13. Chang L-W. 2012. Development of molecular diagnostic tests for Inclusion body disease 683 
in boid snakes. PhD Thesis. University of Florida, Florida. 684 
14. Korzyukov Y, Hetzel U, Kipar A, Vapalahti O, Hepojoki J. 2016. Generation of Anti-685 
Boa Immunoglobulin Antibodies for Serodiagnostic Applications, and Their Use to 686 
Detect Anti-Reptarenavirus Antibodies in Boa Constrictor. PLoS One 11:e0158417. 687 
15. Martinez-Sobrido L, Giannakas P, Cubitt B, Garcia-Sastre A, de la Torre, Juan Carlos. 688 
2007. Differential inhibition of type I interferon induction by arenavirus nucleoproteins. J 689 
Virol 81:12696–12703. 690 
16. Martinez-Sobrido L, Zuniga EI, Rosario D, Garcia-Sastre A, de la Torre, Juan Carlos. 691 
2006. Inhibition of the type I interferon response by the nucleoprotein of the prototypic 692 
arenavirus lymphocytic choriomeningitis virus. J Virol 80:9192–9199. 693 
17. Fan L, Briese T, Lipkin WI. 2010. Z proteins of New World arenaviruses bind RIG-I and 694 
interfere with type I interferon induction. J Virol 84:1785–1791. 695 
18. Meyer B, Ly H. 2016. Inhibition of Innate Immune Responses Is Key to Pathogenesis by 696 
Arenaviruses. J Virol 90:3810–3818. 697 
19. Borden KL, Campbell Dwyer EJ, Salvato MS. 1998. An arenavirus RING (zinc-binding) 698 
protein binds the oncoprotein promyelocyte leukemia protein (PML) and relocates PML 699 
nuclear bodies to the cytoplasm. J Virol 72:758–766. 700 
20. Salomoni P, Pandolfi PP. 2002. The role of PML in tumor suppression. Cell 108:165–701 
170. 702 
21. Zimmerman LM, Vogel LA, Bowden RM. 2010. Understanding the vertebrate immune 703 
system: insights from the reptilian perspective. J Exp Biol 213:661–671. 704 
22. Jaffredo T, Fellah JS, Dunon D. 2006. Immunology of Birds and Reptiles. Major 705 
Reference Works. 706 
23. Galabov AS, Velichikova EH. 1975. Interferon production in tortoise peritoneal cells. J 707 
Gen Virol 28:259–263. 708 
24. Mondal S, Rai U. 2001. In vitro effect of temperature on phagocytic and cytotoxic 709 
activities of splenic phagocytes of the wall lizard, Hemidactylus flaviviridis. Comp 710 
Biochem Physiol A Mol Integr Physiol 129:391–398. 711 
25. Mondal S, Rai U. 2002. In vitro effect of sex steroids on cytotoxic activity of splenic 712 
macrophages in wall lizard (Hemidactylus flaviviridis). Gen Comp Endocrinol 125:264–713 
271. 714 
26. Shang S, Zhong H, Wu X, Wei Q, Zhang H, Chen J, Chen Y, Tang X, Zhang H. 2018. 715 
Genomic evidence of gene duplication and adaptive evolution of Toll like receptors 716 
(TLR2 and TLR4) in reptiles. International Journal of Biological Macromolecules 717 
109:698–703. 718 
27. Voogdt CGP, Bouwman LI, Kik MJL, Wagenaar JA, van Putten, Jos P. M. 2016. Reptile 719 
Toll-like receptor 5 unveils adaptive evolution of bacterial flagellin recognition. 720 
Scientific Reports 6:19046 EP -. 721 
28. Zhou Y, Liang Q, Li W, Gu Y, Liao X, Fang W, Li X. 2016. Characterization and 722 
functional analysis of toll-like receptor 4 in Chinese soft-shelled turtle Pelodiscus 723 
sinensis. Developmental & Comparative Immunology 63:128–135. 724 
29. Merchant M, Williams S, Trosclair PL3, Elsey RM, Mills K. 2007. Febrile response to 725 
infection in the American alligator (Alligator mississippiensis). Comp Biochem Physiol 726 
A Mol Integr Physiol 148:921–925. 727 
30. Kluger MJ, Ringler DH, Anver MR. 1975. Fever and survival. Science 188:166–168. 728 
31. A Farag M, El Ridi R. 1985. Mixed leucocyte reaction (MLR) in the snake Psammophis 729 
sibilans. Immunology 55. 730 
32. El Ridi R, Zada S, Afifi A, El Deeb S, El Rouby S, Farag M, Saad A-H. 1988. Cyclic 731 
changes in the differentiation of lymphoid cells in reptiles. Cell Differentiation 24:1–8. 732 
33. Munoz FJ, La Fuente M de. 2001. The effect of the seasonal cycle on the splenic 733 
leukocyte functions in the turtle Mauremys caspica. Physiol Biochem Zool 74:660–667. 734 
34. Ansar Ahmed S, Penhale WJ, Talal N. 1985. Sex hormones, immune responses, and 735 
autoimmune diseases. Mechanisms of sex hormone action. Am J Pathol 121:531–551. 736 
35. Klein SL. 2004. Hormonal and immunological mechanisms mediating sex differences in 737 
parasite infection. Parasite Immunol 26:247–264. 738 
36. Saad AH. 1989. Sex-associated differences in the mitogenic responsiveness of snake 739 
blood lymphocytes. Developmental & Comparative Immunology 13:225–229. 740 
37. Gambon-Deza F, Sanchez-Espinel C, Mirete-Bachiller S, Magadan-Mompo S. 2012. 741 
Snakes antibodies. Developmental & Comparative Immunology 38:1–9. 742 
38. Warr GW, Magor KE, Higgins DA. 1995. IgY: clues to the origins of modern antibodies. 743 
Immunol Today 16:392–398. 744 
39. Coe JE, Leong D, Portis JL, Thomas LA. 1976. Immune response in the garter snake 745 
(Thamnophis ordinoides). Immunology 31:417–424. 746 
40. Kendall Salanitro S. 1973. Immune Response of Snakes. Copeia 1973:504–515. 747 
41. Chang L, Fu D, Stenglein MD, Hernandez JA, DeRisi JL, Jacobson ER. 2016. Detection 748 
and prevalence of boid inclusion body disease in collections of boas and pythons using 749 
immunological assays. Vet J 218:13–18. 750 
42. Dervas E, Hepojoki J, Laimbacher A, Romero-Palomo F, Jelinek C, Keller S, Smura T, 751 
Hepojoki S, Kipar A, Hetzel U. 2017. Nidovirus-Associated Proliferative Pneumonia in 752 
the Green Tree Python (Morelia viridis). J Virol. 753 
43. Hepojoki J, Kipar A, Korzyukov Y, Bell-Sakyi L, Vapalahti O, Hetzel U, Ross SR. 2015. 754 
Replication of Boid Inclusion Body Disease-Associated Arenaviruses Is Temperature 755 
Sensitive in both Boid and Mammalian Cells. J Virol 89:1119. 756 
44. Cohen J. 1960. A Coefficient of Agreement for Nominal Scales. Educational and 757 
Psychological Measurement 20:37–46. 758 
45. Chang L-W, Fu A, Wozniak E, Chow M, Duke DG, Green L, Kelley K, Hernandez JA, 759 
Jacobson ER. 2013. Immunohistochemical detection of a unique protein within cells of 760 
snakes having inclusion body disease, a world-wide disease seen in members of the 761 
families Boidae and Pythonidae. PLoS One 8:e82916. 762 
46. Hepojoki J, Kipar A, Korzyukov Y, Bell-Sakyi L, Vapalahti O, Hetzel U, Ross SR. 2015. 763 
Replication of Boid Inclusion Body Disease-Associated Arenaviruses Is Temperature 764 
Sensitive in both Boid and Mammalian Cells. J Virol 89:1119. 765 
47. Elliott R. Jacobson. 2007. Infectious Diseases and Pathology of Reptiles: Color Atlas and 766 
Text, 1st ed. CRC Press Inc, Boca Raton. 767 
48. Ujvari B, Madsen T. 2011. Do natural antibodies compensate for humoral 768 
immunosenescence in tropical pythons? Functional Ecology 25:813–817. 769 
49. Holodick NE, Rodríguez-Zhurbenko N, Hernández AM. 2017. Defining Natural 770 
Antibodies. Frontiers in immunology 8:872. 771 
50. Mims CA. 1981. Vertical transmission of viruses. Microbiol Rev 45:267–286. 772 
51. Hotchin J, Weigand H. 1961. Studies of lymphocytic choriomeningitis in mice. I. The 773 
relationship between age at inoculation and outcome of infection. J Immunol 86:392–774 
400. 775 
52. Zhou X, Ramachandran S, Mann M, Popkin DL. 2012. Role of lymphocytic 776 
choriomeningitis virus (LCMV) in understanding viral immunology: past, present and 777 
future. Viruses 4:2650–2669. 778 
53. Thomsen AR, Volkert M, Marker O. 1985. Different isotype profiles of virus-specific 779 
antibodies in acute and persistent lymphocytic choriomeningitis virus infection in mice. 780 
Immunology 55:213–223. 781 
54. Aubert RD, Kamphorst AO, Sarkar S, Vezys V, Ha S-J, Barber DL, Ye L, Sharpe AH, 782 
Freeman GJ, Ahmed R. 2011. Antigen-specific CD4 T-cell help rescues exhausted CD8 783 
T cells during chronic viral infection. Proceedings of the National Academy of Sciences 784 
of the United States of America 108:21182–21187. doi:10.1073/pnas.1118450109. 785 
55. Oxenius A, Zinkernagel RM, Hengartner H. 1998. Comparison of activation versus 786 
induction of unresponsiveness of virus-specific CD4+ and CD8+ T cells upon acute 787 
versus persistent viral infection. Immunity 9:449–457. 788 
56. Borrow P, Martinez-Sobrido L, de la Torre, Juan Carlos. 2010. Inhibition of the type I 789 
interferon antiviral response during arenavirus infection. Viruses 2:2443–2480. 790 
  791 
FIGURE LEGENDS 792 
Figure 1. May-Grünwald-Giemsa stained blood smear, BIBD-positive snake (animal no. 793 
1.25). Erythrocytes frequently exhibit intracytoplasmic inclusion bodies (arrows). 794 
 795 
Figure 2. Association of BIBD, sex and body weight. 796 
 797 
Figure 3. Associations of ELISA test results with age and BIBD status. A) UGV1 IgY, B) 798 
UGV1 IgM, C) UHV1 NP IgY, D) UHV1 NP IgM, E) UHV1 NPC IgY, F) UHV1 NPC IgM. 799 
The red lines indicate the ELISA cut-off point.. 800 
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Figure 4. Association of body weight and UGV-1 IgY antibodies in female and male snakes. 802 
 803 
Figure 5. ELISA results including cut-off values for UGV-1 IgY and IgM, UHV NP IgY and 804 
IgM, UHV NP-C IgY and IgM antibodies in BIBD-positive and BIBD-negative snakes. 805 
 806 
Figure 1. May-Grünwald-Giemsa stained blood smear, BIBD-positive snake (animal no.
1.25). Erythrocytes frequently exhibit intracytoplasmic inclusion bodies (arrows).
Figure 2. Association of BIBD, sex and body weight.
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Figure 3 (A to F). Associations of ELISA test results with age and BIBD status. A) UGV1 IgY, B) UGV1 IgM, C) UHV1 NP
IgY, D) UHV1 NP IgM, E) UHV1 NPC IgY, F) UHV1 NPC IgM. The red lines indicate the ELISA cut-off point.
Figure 4. Association of body weight and UGV-1 IgY antibodies in female and male
snakes.
Figure 3 (A to F). Associations of ELISA test results with age and BIBD status. A) UGV1 IgY, B) UGV1 IgM, C) UHV1 NP
IgY, D) UHV1 NP IgM, E) UHV1 NPC IgY, F) UHV1 NPC IgM. The red lines indicate the ELISA cut-off point.
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Table 1. Animals included into the study 
A. Animals with BIBD (diagnosis based on the detection of intracytoplasmic inclusion 
bodies in blood cells, using blood smears) 
 
         
Animal           
(number) 
Age           
(years) 
Sex 
Weight        
(kg) 
S segment 
WB ELISA 
UGV-1 UGV-1 UHV NP UHV NP-C 
UGV-2 S5-like TSMV-2  IgY IgM IgY     IgM IgY IgM IgY IgM 
1.01 2 M 1.10 + + + - - - + - - - - 
1.02 2 M 2.10 + + + ++ ++ - + - - - - 
1.03 3 M 1.40 + + + + ++ - - - - - - 
1.04 3 M 1.80 + + - ++ + + + - - - - 
1.05 3 M 3.00 + + - - + - - + - + - 
1.06 3 F 1.00 + + - ++ + - - - - - - 
1.07 3 F 1.50 + - - +++ +++ + + + + + + 
1.08 4 M 1.40 + + + + + - + - - - - 
1.09 4 M 1.60 + + + +++ - - + - - - - 
1.10 4 M 2.20 + + + ++ +++ - - - - - - 
1.11 4 F 2.50 + + - - - - - - - - - 
1.12 4 F 2.60 + + - - - - - - - - - 
1.13 4 F 3.30 + + + + + - - - - - - 
1.14 4 F 3.40 + + - + + - - + + + + 
1.15 4 F 3.40 + + - + - - + - - - - 
1.16 4 F 3.40 + + + + +++ - + - - - - 
1.17 4 F 3.70 + + + - - - - - - - - 
1.18 4 F 3.90 + + + +++ +++ + + + + + + 
1.19 4 F 4.10 + + - + + - - - - - - 
1.20 5 M 0.90 + + + - ++ - + - + - + 
1.21 5 M 1.10 + + + - - - + - - - - 
1.22 5 M 1.60 + + + +++ +++ + + - - + + 
1.23 5 M 2.80 + - - - ++ - + - - - - 
1.24 5 F 1.70 + + + + ++ - - - - - - 
1.25 5 F 2.60 + + + - + - - - - - - 
1.26 5 F 4.50 + + + + ++ - - - - - - 
1.27 6 M 1.80 + + + + + - + - - + - 
1.28 6 M 3.20 + + + - ++ + + - - - + 
1.29 6 F 2.70 + + + ++ - - + - + - + 
1.30 6 F 5.50 + + + +++ +++ + + - + - + 
1.31 7 F 9.00 + + + + + + n.a. - - - - 
1.32 n.a. M 2.40 + + + + + - + + - - + 
1.33 n.a. M 2.70 - + + + - + + + + + + 
1.34 n.a. M 3.10 + + + ++ ++ + - - - - - 
n.a. – not available; F – female; M – male; S segment – reptareavirus S segment determined by RT-PCR; WB – 
Western Blot; Western Blot results graded according to signal intensity: - (negative), + (weakly positive), ++ 
(moderately positive), +++ (strongly positive); ELISA – Enzyme linked immunosorbent assay  
  
B. Animals without BIBD (i.e. no evidence of intracytoplasmic inclusion bodies in blood cells, 
using blood smears) 
 
         
Animal           
(number) 
Age           
(years) 
Sex 
Weight        
(kg) 
S segment 
WB ELISA 
UGV-1 UGV-1 UHV NP UHV NP-C 
UGV-2 S5-like TSMV-2  IgY IgM IgY IgM IgY IgM IgY IgM 
2.01 2 M 0.9 - + + ++ + - + + + + + 
2.02 2 M 1.5 - + + ++ +++ - + + - + + 
2.03 2 F 1.3 - + + - + - - - - + + 
2.04 3 M 1.2 - + + +++ ++ + + - - + + 
2.05 3 M 1.3 + + + - - - + + - + + 
2.06 3 M 1.7 - + + + +++ - - - - - - 
2.07 3 M 1.8 - + + - ++ - + - - + - 
2.08 3 F 2.2 - + + - - - + - - - - 
2.09 4 M 2.1 + + + +++ ++ + - + - - - 
2.10 4 M 2.7 + + + +++ +++ - + - + - - 
2.11 4 M 3.3 + + + ++ ++ + - + + + + 
2.12 4 F 3.7 - + + +++ +++ + + + - + + 
2.13 4 F 3.8 - + + ++ ++ + + + + + + 
2.14 4 F 5.8 - + + +++ ++ + + - - - - 
2.15 4 F 6.8 - - - - - - - - - - - 
2.16 5 M 2.2 + + + - - + - + - + + 
2.17 5 M 2.5 - + + + + - - + + + + 
2.18 5 F 5.0 + - + - + + - - - - - 
2.19 5 F 5.3 - + - ++ + + + - - - - 
2.20 5 F 5.3 - - - + - + - - - - - 
2.21 5 F 5.5 - + + ++ - + - + - + + 
2.22 5 F 5.7 - - + ++ - + + + + + + 
2.23 5 F 6.1 - + + +++ + + - + - - - 
2.24 6 M 2.5 + + + - - + - - - - - 
2.25 6 M 3.4 + + + - - + + - - - - 
2.26 6 M 3.5 - + + - + - - - - - - 
2.27 6 F 3.1 - - - +++ +++ + + + + + - 
2.28 6 F 5.6 - + + +++ +++ + - - - - - 
2.29 7 M 3.3 + + - - ++ - - - - - - 
2.30 7 M 4.0 - + + +++ + + - - - - - 
2.31 7 F 5.0 + - + +++ +++ + - + - + - 
2.32 7 F 7.0 - + + +++ +++ + - + + + + 
2.33 7 F 7.5 - + + ++ ++ + + - - - + 
2.34 7 F 10.0 - + + +++ +++ + - + + + + 
2.35 8 M 3.4 - + + +++ + + - + + + + 
2.36 8 F 7.0 - - - +++ ++ + + - - + + 
 
Table 2. Results of inclusion body detection in blood cells (i.e. diagnosis of BIBD) against population parameters. Univariate analysis and stratification 
by sex. 
  
Sex 
(Row%) 
(Col%) 
Weight* 
(95% CI) 
N= 70 
Age**(n) 
(95% CI) 
N=67 
  M F All M F All M F All 
BIBD - 
17 
(47.22%) 
(50.00%) 
19 
(52.78%) 
(52.78 %) 
36 
(100.00%) 
(51.43%) 
2.238 
(1.788 – 2.801) 
4.912 
(3.919 – 6.156) 
3.389 
(2.767 – 4.149) 
4.588 (17) 
(3.643 – 5.534) 
5.211 (19) 
(4.464 – 5.957) 
4.917 (36) 
(4.343 – 5.491) 
BIBD + 
17 
(50.00%) 
(50.00%) 
17 
(50.00%) 
(47.22%) 
34 
(100.00%) 
(48.57%) 
1.876 
(1.532 – 2.297) 
3.077 
(2.373 – 3.991) 
2.403 
(2.010 – 2.873) 
4.071 (14) 
(3.305 – 4.838) 
4.471 (17) 
(3.922 – 5.019) 
4.290 (31) 
(3.854 – 4.726) 
All 
34 
 (48.57%) 
(100.00%) 
36 
(51.36%) 
(100.00%) 
70 
(100.00%) 
(100.00%) 
2.049 
(1.770 – 2.372) 
3.938 
(3.287 – 4.719) 
2.867 
(2.497 – 3.293) 
4.355 (31) 
(3.759 – 4.950) 
4.861 (36) 
(4.395 – 5.327) 
4.627 (67) 
(4.260 – 4.994)  
χ2=0.054, p=0.816 t=1.2365, df=32 
p=0.2253 
t=2.8801, df=34 
p<0.01 
t=2.5748, df=68 
p<0.05 
t=0.8785, df=29 
p=0.3869 
t=1.6494, df=34 
p=0.1083 
t=1.7226, df=65 
p=0.0897 
*Kg, geometric mean  
**Years 
 
Table 3. Multiple linear regression: Factors associated with Weight (Kg log10) (n =67) 
Factors Adjusted b (95% CI) P-value 
Sex (Female) 0.255 (0.178 – 0.333) < 0.001 
Inclusion detection (positive) -0.107 (-0.185 – - 0.293 < 0.01 
Age (years) 0.084 (0.058 – 0.110) < 0.001 
Multiple linear regression (AdjR
2
 = 0.6374). 
 
Table 4. Summary of RT-PCR results including test agreement and sensitivity/specificity with inclusion detection considered the gold standard 
  
 
BIBD 
Total Cohen’s κ Sensitivity 
(95%CI) 
Specificity 
(95%CI)     +ve -ve 
UGV-2 
+ve 33 10 43 κ=Ϭ.688 
(0.524 – 0.852) 
97.06%  
(93.10 – 100)% 
72.22%  
(61.73 – 82.71)% -ve 1 26 27 
S5-like 
+ve 32 29 61 κ=Ϭ.ϭ33 
(-0.019 – 0.284) 
94.12%  
(88.61 – 99.63)% 
19.44%  
(10.17 – 28.72)% -ve 2 7 9 
TSMV-2 
+ve 24 30 54 κ=-0.125 
(-0.320 – 0.069) 
70.59  
(59.91 – 81.26)% 
16.67%  
(7.94 – 25.40)% -ve 10 6 16 
Any 
segment 
+ve 34 32 66 κ=Ϭ.ϭ08 
(0.005 – 0.212) 100% 
11.11%  
(3.75 – 18.47)% -ve 0 4 4 
Total   34 36 70  
 
Table 5.  RT-PCR results against population parameters, univariate analysis including stratification by sex 
  
Sex 
(Row%) 
(Col%) 
Weight* 
(95% CI) 
N= 70 
Age**(n) 
(95% CI) 
N=67 
  M F Total M F Total M F Total 
UGV 
RT-PCR 
-ve 
10 
(37.04%) 
(29.41%) 
17 
(62.96%) 
(47.22%) 
27 
(100.00%) 
(38.57%) 
2.090 
(1.466 – 2.981) 
4.901 
(3.796 – 6.328) 
3.575 
(2.772 – 4.609) 
4.333 (9) 
(2.615 – 6.052) 
5.118 (17) 
(4.307 – 5.928) 
4.846 (26) 
(4.108 – 5.583) 
UGV 
RT-PCR 
+ve 
24 
(55.81%) 
(70.59%) 
19 
(44.19%) 
(52.78%) 
43 
(100.00%) 
(61.43%) 
2.032 
(1.720 – 2.400) 
3.238506        
2.544208   
4.122274 
2.497 
(2.142 – 2.910) 
4.355 (22) 
(3.759 – 4.969) 
4.632 (19) 
(4.070 – 5.193) 
4.488 (41) 
(4.088 – 4.555) 
 χ2=2.341, p=0.126 t=0.1768, df=32 
p=0.8608 
t=2.4882, df=34 
p<0.05 
t=2.622, df=68 
p<0.05 
t= -0.046, df=29 
p=0.9633 
t=1.0597, df=34 
p=0.2968 
t=0.9485, df=65 
p=0.346 
S5-like 
RT-PCR 
-ve 
1 
(11.11%) 
(2.94%) 
8 
(88.89%) 
(22.22%) 
9 
(100.00%) 
(12.86%) 
2.800 
4.497 
(2.937 – 6.884) 
4.266 
(2.900 – 6.275) 
5.000 (1) 
 
5.375 (8) 
(4.039 – 6.711) 
5.333 (9) 
(4.180 – 6.486) 
S5-like 
RT-PCR 
+ve 
33 
(54.10%) 
(97.06%) 
28 
(45.90%) 
(77.78%) 
61 
(100.00% 
(87.14%) 
2.030 
(1.748 – 2.357) 
3.792 
(3.070 – 4.684) 
2.704 
(2.336 – 3.130) 
4.333 (30) 
(3.718 – 4.948) 
4.714 (28) 
(4.210 – 5.219) 
4.517 (58) 
(4.126 – 4.909) 
 χ2=5.8019, p<0.05 t=…, df=ϯϮ p=… 
t=0.791, df=34 
p=0.4344 
t=2.264, df=68 
p<0.05 
t=…, df=29 
p=.... 
t=1.2051, df=34 
p=0.2365 
t=1.528, df=65 
p=0.131 
TSMV-2 
RT-PCR 
-ve 
4 
(25.00%) 
(11.76%) 
12 
(75.00%) 
(33.33%) 
16 
(100.00%) 
(22.86%) 
2.658 
(1.734 – 4.074) 
3.338 
(2.301 – 4.842) 
3.153 
(2.383 – 4.172) 
4.500 (4) 
(1.453 – 7.547) 
4.500 (12) 
(3.622 – 5.378) 
4.5 (16) 
(3.722 – 5.278) 
TSMV-2 
RT-PCR 
+ve 
30 
(55.56%) 
(88.24%) 
24 
(44.44%) 
(66.67%) 
54 
(100.00%) 
(77.14%) 
1.979 
(1.688 – 2.321) 
4.278 
(3.464 – 5.283) 
2.788 
(2.368 – 3.282) 
4.333 (27) 
(3.694 – 4.973) 
5.042 (24) 
(4.395 – 5.619) 
4.667 (51) 
(4.236 – 5.098) 
 χ2=4.6133, p<0.05 t=1.3371, df=32 
p=0.1906 
t=-1.3264, df=34 
p=0.1936 
t=0.743, df=68 
p=0.460 
t=1.1885, df=29 
P=0.8518 
t=-1.1170, df=34 
p=0.2718 
t=-0.384, df=65 
p=0.702 
Total 
34 
(48.57%) 
(100.00%) 
36 
(51.43%) 
(100.00%) 
70 
(100.00%) 
(100.00%) 
2.049 
(1.770 – 2.372) 
3.938 
(3.287 – 719) 
2.867 
(2.497 – 3.293) 
4.355 (31) 
(3.759 – 4.950) 
4.861 (36) 
(4.395 – 5.329) 
4.626 (67) 
(4.260 – 4.994) 
*Kg, geometric mean  
**Mean Years 
 
  
           |          Sex 
        S4 |      Male     Female |     Total 
-----------+----------------------+---------- 
  negative |        10         17 |        27  
           |     37.04      62.96 |    100.00  
           |     29.41      47.22 |     38.57  
-----------+----------------------+---------- 
  positive |        24         19 |        43  
           |     55.81      44.19 |    100.00  
           |     70.59      52.78 |     61.43  
-----------+----------------------+---------- 
     Total |        34         36 |        70  
           |     48.57      51.43 |    100.00  
           |    100.00     100.00 |    100.00  
 
          Pearson chi2(1) =   2.3410   Pr = 0.126 
           Fisher's exact =                 0.147 
   1-sided Fisher's exact =                 0.099 
Table 6. Results of the detection of IgY and IgM plasma antibodies against UGV-1 virions using WB in comparison to the diseases status (BIBD-positive or –
negative, based on the presence of cytoplasmic IB in blood cells 
Western blotting 
BIBD Cohen’s κ Sensitivity 
(95%CI) 
Specificity 
(95%CI) +ve -ve Total 
WB UGV1 IgY 
+ve 24 25 49 κ = 0.011 
(-0.195 – 0.218) 
70.59%  
(59.91 – 81.26)% 
30.56%  
(19.76 – 41.35)% -ve 10 11 21 
WB UGV1 IgM 
+ve 25 27 52 κ = -0.015 
(-0.222 – 0.193) 
73.53%  
(63.19 – 83.86)% 
25.00%  
(14.86 – 35.14)% -ve 9 9 18 
Total 34 36 70  
 
Table 7. ELISA results against RT-PCR and IB detection  
ELISA 
Alternative test 
UGV1 IgY* (n) 
(95%CI) 
UGV1 IgM* GM (n) 
(95%CI) 
UHV1 NP IgY* (n) 
(95%CI) 
UHV1 NP IgM* (n) 
(95%CI) 
UHV-1 NP-C IgY* (n) 
(95%CI) 
UHV-1 NP-C IgM* (n) 
(95%CI) 
BIBD +ve 
0.155 (33) 
(0.095 – 0.252) 
0.561 (33) 
(0.479 – 0.657) 
0.156 (34) 
(0.114 – 0.213) 
0.250 (34) 
(0.202 – 0.308) 
0.251 (34) 
(0.191 – 0.329) 
0.290 (34) 
(0.241 – 0.351) 
BIBD -ve 
0.553 (36) 
(0.337 – 0.906) 
0.448 (36) 
(0.399 – 0.503) 
0.306 (36) 
(0.244 – 0.385) 
0.255 (36) 
(0.199 – 0.327) 
0.556 (36) 
(0.452 – 0.682) 
0.379 (36) 
(0.339 – 0.422) 
t-test 
 t = 3.7246, df=67 
P<0.001 
t = -2.3586, df=67 
p<0.05 
t = 3.5899, df=68 
p<0.001 
t = 0.1294, df=68 
p=0.903 
t = 4.771, df=68 
p<0.001 
t = 2.5368, df=68 
p<0.05 
UGV-2 RT-PCR +ve 
0.209 (42) 
(0.133 – 0.329) 
0.464 (42) 
(0.398 – 0.540) 
0.173 (43) 
(0.132 – 0.226) 
0.254 (43) 
(0.214 – 0.301) 
0.282 (43) 
(0.221 – 0.361) 
0.296 (43) 
(0.254 – 0.344) 
UGV-2 PR-PCR -ve 
0.530 (27) 
(0.288 – 0.975) 
0.464 (27) 
(0.458 – 0.596) 
0.326 (27) 
(0.251 – 0.123) 
0.249 (27) 
(0.179 – 0.346) 
0.598 (27) 
(0.480 – 0.744) 
0.402 (27) 
(0.356 – 0.454) 
t-test 
t = 2.5322, df=67 
p<0.05 
t = -1.181, df=67 
p=0.2118 
t = 3.2325, df=68 
p<0.01 
t = -0.1199, df=68 
p=0.9049 
t = 4.2732, df=68 
p<0.001 
t = 2.9145, df=68 
p<0.01 
S5-like RT-PCR +ve 
0.262 (60) 
(0.180 – 0.382) 
0.495 (60) 
(0.445 – 0.551) 
0.207 (61) 
(0.168 – 0.256) 
0.251 (61) 
(0.210 – 0.301) 
0.353 (61) 
(0.292 – 0.427) 
0.333 (61) 
(0.295 – 0.375) 
S5-like PT-PCR -ve 
0.745 (9) 
(0.171 – 0.324) 
0.522 (9) 
(0.378 – 0.718) 
0.339 (9) 
(0.156 – 0.733) 
0.260 (9) 
(0.197 – 0.344) 
0.592 (9) 
(0.263 – 1.330) 
0.335 (9) 
(0.295 – 0.375) 
t-test 
t = 1.9239, df=67 
p=0.0586 
t = 0.3602, df=67 
p=0.7199 
t = 1.6353, df=68 
p=0.1068 
t = 0.1522, df=68 
p=0.8795 
t = 1.8398, df=68 
p=0.0702 
t = 0.041, df=68 
p=0.9674 
SMTV-2 RT-PCR +ve 
0.334 (53) 
(0.220 – 0.508) 
0.506 (53) 
(0.452 – 0.567) 
0.235 (54) 
(0.192 – 0.289) 
0.259 (54) 
(0.213 – 0.315) 
0.407 (54) 
(0.334 – 0.495) 
0.359 (54) 
(0.320 – 0.402) 
SMTV-2 PT-PCR -ve 
0.212 (16) 
(0.088 – 0.507) 
0.475 (16) 
(0.383 – 0.589) 
0.178 (16) 
(0.098 – 0.546) 
0.230 (16) 
(0.179 – 0.296) 
0.292 (16) 
(0.171 – 0.500) 
0.258 (16) 
(0.198 – 0.337) 
t-test 
t = -1.0373, df=67 
p=0.3033 
t = -0.5349, df=67 
p=0.5945 
t = -1.1503, df=68 
p=0.2541 
t = -0.6136, df=68 
p=0.5415 
t = -1.4677, df=68 
p=0.1468 
t = -2.6477, df=68 
p<0.05 
Total 
0.301 (69) 
(0.207 – 0.436) 
0.499 (69) 
(0.452 – 0.550) 
0.221 (70) 
(0.180 – 0.270) 
0.252 (70) 
(0.215 – 0.296) 
0.377 (70) 
(0.312 – 0.456) 
0.333 (70) 
(0.299 – 0.371) 
*Optical density geometric mean 
 
 
Table 8. Associations between ELISA results and population parameters, univariate analysis 
  
Sex  
(95%CI) 
Weight 
Linear regression results 
 
Age 
ANOVA results 
OD 
geometric 
mean 
Male Female All p value 
F 
R
2
 
Coef 
Adjusted b 
((95%CI) 
p value F p value 
UGV-1  
RT-PCR IgY 
0.208 
(0.122 – 0.352) 
0.422 
(0.251 – 0.710) 
0.301 
(0.207 – 0.436) 
t = -1.9407, df=67 
p=0.0565 
(1.67) =32.4 
0.316 
-0.245  
(-1.532 - 0.959) 
1.556  
(1.010 – 2.102) p<0.0001 (6,59) =3.52 p<0.01 
UGV1 
RT-PCR IgM 
0.540 
(0.472 – 0.618) 
0.462 
(0.400 – 0.534) 
0.499 
(0.452 – 0.550) 
t = 1.6002, df=67 
p=0.1143 
(1.67) =4.90 
0.0542 
-0.217 
(-0.304 - -0.131) 
-0.188 
(-0.357 – -0.185) 
P<0.05 
(6.59) =1.26 p=0.2876 
UHV-1 NP 
RT-PCR IgY 
0.242 
(0.196 – 0.299) 
0.202 
(0.142 – 0.287) 
0.221 
(0.180 – 0.270) 
t = 0.8919, df=68 
p=0.3756 
(1.68) =0.04 
-0.141 
-0.673 
(-0.858 - 0.487) 
0.036 
(-0.319 – 0.391) p=0.84 (6,60) =1 p=0.4365 
UHV-1 NP 
RT-PCR IgM 
0.265 
(0.228 – 0.308) 
0.241 
(0.181 – 0.320) 
0.252 
(0.215 – 0.296) 
t = 0.5993, df=68 
p=0.5510 
(1,68) =0.43 
-0.0083 
-0.556 
(-0.701 - -0.411) 
-0.092 
(-0.369 – 0.186) p=0.513 (6,60) =0.71 p=0.6398 
UHV-1 NPC 
RT-PCR IgY 
0.382 
(0.298 – 0.489) 
0.373 
(0.276 – 0.504) 
0.377 
(0.312 – 0.456) 
t = 1.1234, df=68 
p=0.9021 
(1,68) =0.86 
-0.0021 
-0.494 
(-0.666 – -0.321) 
0.153 
(-0.178 – 0.485) p=0.358 (6,60) =1.45 p=0.2093 
UHV-1 NP-C 
RT-PCR IgM 
0.335 
(0.294 – 0.381) 
0.331 
(0.277 – 0.396) 
0.333 
(0 .299 – 0.371) 
t = 0.1052, df=68 
p=0.9165 
(1,68) =0.71 
-0.0041 
-0.514 
(-0.312 – -0.416) 
0.080 
(-0.108 – 0.268) p=0.401 (6,60) =0.77 p=0.598 
 
Table 9. Results obtained from the examination of UGV-2, S5-like and TSMV-2 specific S-segments by 
RT-PCR and UGV-1, UHV-1 NP and UHV-1 NP-C specific IgY and IgM antibodies by ELISA  
 
 
A. Animals with BIBD   
Pos – positive; Neg - negative 
 
 
  
RT-PCR 
UGV-1 UHV-1 NP UHV-1 NP-C 
IgY    
IgM                
n=33 tested 
IgY and IgM            
n=33 tested 
IgY    IgM             IgY and IgM            IgY    IgM             IgY and IgM            
Positive 
34/34 
(100%) 
Pos    
 9/34                     
(26.47%) 
Pos       
19/33 
(57.58%) 
Pos       
7/33 
(21.21%) 
Pos      
6/34 
(17.65%) 
Pos      
7/34 
(20.59%) 
Pos       
4/34 
(11.76%) 
Pos      
7/34 
(20.59%) 
Pos      
10/34 
(29.41%) 
Pos       
5/34 
(14.71%) 
Neg 25/34 
(73.53%) 
Neg       
14/33 
(42.42%) 
Neg     
13/33 
(39.39%) 
Neg    
28/34 
(82.35%) 
Neg      
27/34 
(79.41%) 
Neg    
25/34 
(73.53%) 
Neg    
27/34 
(79.41%) 
Neg      
24/34 
(70.59%) 
Neg     
22/34 
(64.71%) 
3 Segments        
23/34 
(67.65%) 
Pos    
6/23 
(26.09%) 
Pos       
14/22 
(63.64%) 
Pos      
4/22 
(18.18%) 
Pos      
2/23 
(8.7%) 
Pos      
4/23 
(17.39%) 
Pos      
1/23 
(4.35%) 
Pos      
3/23 
(13.04%) 
Pos      
7/23 
(30.43%) 
Pos      
2/23  
(8.7%) 
Neg 17/23 
(73.91%) 
Neg         
8/22 
(36.36%) 
Neg     
7/22 
(31.82%) 
Neg    
21/23 
(91.3%) 
Neg       
19/23 
(82.61%) 
Neg     
18/23 
(78.26%) 
Neg    
20/23 
(86.96%) 
Neg        
16/23 
(69.57%) 
Neg    
15/23 
(65.22%) 
2 Segments 
9/34 
(26.47%) 
Pos 
2/9 
(22.22%) 
Pos         
3/9  
(33.33%) 
Pos    
2/9  
(22.22%) 
Pos       
3/9 
(33.33%) 
Pos        
2/9 
(22.22%) 
Pos         
2/9 
(22.22%) 
Pos       
3/9 
(33.33%) 
Pos        
2/9 
(22.22%) 
Pos         
2/9 
(22.22%) 
Neg      
7/9 
(77.78%) 
Neg        
6/9  
(66.67%) 
Neg    
6/9  
(66.67%) 
Neg      
6/9 
(66.67%) 
Neg       
7/9 
(77.78%) 
Neg    
6/9 
(66.67%) 
Neg      
6/9 
(66.67%) 
Neg       
7/9 
(77.78%) 
Neg    
6/9 
(66.67%) 
1 Segment 
2/34 
(5.88%) 
Pos       
1/2  
(50%) 
Pos       
2/2  
(100%) 
Pos    
1/2  
(50%) 
Pos       
1/2  
(50%) 
Pos       
1/2  
(50%) 
Pos       
1/2  
(50%) 
Pos       
1/2  
(50%) 
Pos       
1/2  
(50%) 
Pos       
1/2  
(50%) 
Neg      
1/2  
(50%) 
Neg      
0/2  
(0%) 
Neg    
0/2  
(0%) 
Neg      
1/2  
(50%) 
Neg      
1/2  
(50%) 
Neg      
1/2  
(50%) 
Neg      
1/2  
(50%) 
Neg      
1/2  
(50%) 
Neg      
1/2  
(50%) 
  
B. Animals without BIBD 
 
    
 
RT-PCR 
UGV-1 UHV-1 NP UHV-1 NP-C 
IgY    IgM             IgY and IgM            IgY    IgM             IgY and IgM            IgY    IgM             IgY and IgM            
Positive/ 
Negative                  
36/36 
(100%) 
Pos    
24/36 
(66.67%) 
Pos       
16/36 
(44.44%) 
Pos     
10/36 
(27.78%) 
Pos    
17/36 
(47.22%) 
Pos      
9/36 
(25%) 
Pos     
8/36 
(22.22%) 
Pos    
19/36 
(52.78%) 
Pos      
17/36 
(47.22%) 
Pos     
16/36 
(44.44%) 
Neg   
12/36 
(33.33%) 
Neg      
20/36 
(55.56%) 
Neg      
6/36 
(16.67%) 
Neg   
19/36 
(52.78%) 
Neg     
27/36 
(75%) 
Neg      
18/36  
(50%) 
Neg   
17/36 
(47.22%) 
Neg     
19/36 
(52.78%) 
Neg      
16/36 
(44.44%) 
Positive           
32/36 
(88.89%) 
Pos   
21/32 
(65.63%) 
Pos     
14/32 
(43.75%) 
Pos      
8/32 
(25.00%) 
Pos   
16/32 
(50%) 
Pos     
9/32 
(28.13%) 
Pos      
8/32 
(25.00%) 
Pos   
17/32 
(53.13%) 
Pos   
16/32 
(50%) 
Pos      
15/32 
(46.88%) 
Neg   
11/32 
(34.38%) 
Neg    
18/32 
(56.25%) 
Neg      
5/32 
(15.63%) 
Neg   
16/32 
(50%) 
Neg  
23/32 
(71.88%) 
Neg      
15/32 
(46.88%) 
Neg   
15/32 
(46.88%) 
Neg   
16/32 
(50%) 
Neg      
14/32 
(43.75%) 
3 Segments        
7/32 
(21.88%) 
Pos     
5/7 
(71.43%) 
Pos      
3/7  
(42.86%) 
Pos     
1/7  
(14.29%) 
Pos     
4/7 
(57.14%) 
Pos      
2/7 
(28.57%) 
Pos     
1/7  
(14.29%) 
Pos      
3/7 
(42.86%) 
Pos      
3/7 
(42.86%) 
Pos      
3/7  
(42.86%) 
Neg    
2/7 
(28.57%) 
Neg      
4/7  
(57.14%) 
Neg     
0/7  
(0%) 
Neg    
 3/7 
(42.86%) 
Neg      
5/7 
(71.43%) 
Neg    
2/7  
(28.57%) 
Neg      
4/7 
(57.14%) 
Neg      
4/7 
(57.14%) 
Neg      
4/7  
(57.14%) 
2 Segments        
23/32 
(71.88%) 
Pos   
14/23 
(60.87%) 
Pos     
9/23 
(39.13%) 
Pos     
5/23 
(21.74%) 
Pos   
11/23 
(47.83%) 
Pos    
6/23 
(26.09%) 
Pos     
6/23 
(26.09%) 
Pos   
13/23 
(56.52%) 
Pos    
12/23 
(52.17%) 
Pos   
11/23 
(47.83%) 
Neg     
9/23 
(39.13%) 
Neg    
14/23 
(60.87%) 
Neg    
5/23 
(21.74%) 
Neg    
12/23 
(52.17%) 
Neg   
17/23 
(73.91%) 
Neg     
12/23 
(52.17%) 
Neg    
10/23 
(43.48%) 
Neg    
11/23 
(47.83%) 
Neg    
9/23 
(39.13%) 
1 Segment               
2/32 
(6.25%) 
Pos    
2/2  
(100%) 
Pos      
2/2  
(100%) 
Pos    
2/2  
(100%) 
Pos    
1/2  
(50%) 
Pos    
1/2  
(50%) 
Pos    
1/2  
(50%) 
Pos    
1/2  
(50%) 
Pos    
1/2 
(50%) 
Pos    
1/2  
(50%) 
Neg   
0/2  
(0%) 
Neg     
 0/2  
(0%) 
Neg   
 0/2  
(0%) 
Neg   
1/2  
(50%) 
Neg   
1/2 
(50%) 
Neg   
1/2 
(50%) 
Neg   
1/2  
(50%) 
Neg   
1/2  
(50%) 
Neg   
1/2  
(50%) 
Negative                  
4/36 
(11.11%) 
Pos   
3/4  
(75%) 
Pos      
2/4  
(50%) 
Pos   
2/4  
(50%) 
Pos   
1/4  
(25%) 
Pos      
0/4  
(0%) 
Pos      
0/4  
(0%) 
Pos   
2/4  
(50%) 
Pos   
1/4  
(25%) 
Pos   
1/4  
(25%) 
Neg   
1/4  
(25%) 
Neg      
2/4  
(50%) 
Neg   
1/4  
(25%) 
Neg   
3/4  
(75%) 
Neg      
4/4 
(100%) 
Neg   
3/4  
(75%) 
Neg      
2/4  
(50%) 
Neg   
3/4  
(75%) 
Neg   
2/4  
(50%) 
Table 10. ELISA results based on the cut-off points against inclusion detection including test agreement and 
sensitivity/Specificity 
ELISA test 
BIBD Cohen’s κ 
(95%CI) 
Sensitivity Specificity 
+ve -ve Total 
UGV1 IgY 
+ve 25 11 34 κ = 0.429 
(0.213 – 0.645) 
73.53% 
(63.19 – 83.86) % 
69.44% 
(58.65 – 80.24) % -ve 9 25 36 
UGV1 IgM* 
+ve 14 20 34 κ = -0.131 
(-0.360 – 0.097) 
42.42% 
(30.76 – 54.09) % 
44.44% 
(32.72 – 56.17) % -ve 19 16 35 
UHV1 NP IgY 
+ve 28 19 47 κ = 0.293 
(0.075 – 0.510) 
82.35% 
(73.42 – 91.28) % 
47.22% 
(35.53 – 58.92) % -ve 6 17 23 
UHV1 NP IgM 
+ve 7 9 16 κ = 0.043 
(-0.145 – 0.232) 
79.41% 
(69.94 – 88.88) % 
25.00% 
(14.86 – 35.14) % -ve 24 27 54 
UHV1 NP-C IgY 
+ve 27 17 44 κ = 0.319 
(0.100 – 0.539) 
79.41% 
(69.94 – 88.88) % 
52.78% 
(41.08 – 64.47) % -ve 7 19 26 
UHV1 NP-C IgM 
+ve 24 19 43 κ = 0.177 
(-0.051 – 0.405) 
70.59% 
(59.91 – 81.26) % 
47.22% 
(35.53 – 58.92) % -ve 10 17 27 
 Total 34 36 70     
*missing value 
 
 
Table 11. Agreements of ELISA tests with IB detection and RT-PCR 
ELISA test BIBD UGV-2 S5-like SMTV-2  
 
+ve -ve Cohen’s κ +ve -ve  Cohen’s κ 
(95%CI) 
+ve -ve  Cohen’s κ +ve -ve  Cohen’s κ Total 
UGV1 IgY 
+ve 25 11 κ = 0.429 
(0.213 – 0.645) 
28 8 0.339 
(0.119 – 0.558) 
34 2 0.153 
(-0.009 – 0.316) 
26 10 -0.103 
(-0.307 – 0.102) 
36 
-ve 9 25 15 19 27 7 28 6 34 
UGV1 IgM* 
+ve 14 20 κ = -0.131 
(-0.360 – 0.097) 
21 13 0.018 
(-0.209 – 0.244) 
30 4 0.025 
(-0.134 – 0.184) 
25 9 -0.064 
(-0.267 – 0.139) 
34 
-ve 19 16 21 14 30 5 28 7 35 
UHV1 NP IgY 
+ve 28 19 κ = 0.293 
(0.075 – 0.510) 
33 14 0.256 
(0.018 – 0.494) 
42 5 0.080 
(-0.129 – 00289) 
35 12 -0.088 
(-0.307 – 0.131) 
47 
-ve 6 17 10 13 19 4 19 4 23 
UHV1 NP IgM 
+ve 27 27 κ = 0.043 
(-0.145 – 0.232) 
35 19 0.119 
(-0.103 – 0.342) 
47 7 -0.005 
(-0.220 – 0.209) 
40 14 -0.134 
(-0.333 – 0.064) 
54 
-ve 7 9 8 8 14 2 14 2 16 
UHV1 NP-C IgY 
+ve 27 17 κ = 0.319 
(0.100 – 0.539) 
33 11 0.363 
(0.133 – 0.592) 
40 4 0.117 
(-0.083 – 0.318) 
33 11 -0.063 
(-0.284 – 0.159) 
44 
-ve 7 19 10 16 21 5 21 5 26 
UHV1 NP-C IgM 
+ve 24 19 κ = 0.177 
(-0.051 – 0.405) 
31 12 0.276 
(0.037 – 0.515) 
37 6 -0.032 
(-0.209 – 0.144) 
30 13 -0.207 
(-0.400 – -0.014) 
43 
-ve 10 17 12 15 24 3 24 3 27 
 Total 34 36  43 27  61 9  54 16  70 
*missing value 
 
 
Table 12A. IgY ELISA cut-off point results against population parameters, univariate analysis including stratification by sex 
  
Sex 
(Row%) 
(Col%) 
Weight* 
(95% CI) 
N= 70 
Age**(n) 
(95% CI) 
N=67 
  M F Total M F Total M F Total 
UGV- 1 
IgY ELISA 
-ve 
20 
(55.56%) 
(58.82%) 
16 
(44.44%) 
(44.44%) 
36 
(100.00%) 
(51.43%) 
1.809 
(1.484 – 2.206) 
2.788 
(2.167 – 3.588) 
2.193 
(1.858 – 2.589) 
3.947 (19) 
(3.220 – 4.674) 
4.063 (16) 
(3.568 – 4.557) 
4.000 (35) 
(3.567 – 4.329) 
UGV-1 
IgY ELISA 
+ve 
14 
(41.18%) 
(41.18%) 
20 
(58.82%) 
(55.86%) 
34 
(100.00%) 
(48.57%) 
2.448 
(1.995 – 3.004) 
5.192 
(4.283 – 6.293) 
3.809 
(3.159 – 4.594) 
5.000 (12) 
(3.951 – 6.049) 
5.500 (20) 
(4.865 – 6.135) 
5.313 (32) 
(4.783 – 5.842) 
 χ2 = 1.4473, p=0.229 t = -2.1855, df=32 
p<0.05 
t = -4.2166, df=34 
p<0.001 
t = -4.480, df=68 
p<0.0001 
t = -1.8251, df=29 
p=0.0783 
t = -3.609, df=34 
p<0.005 
t = -3.935, df=65 
p<0.001 
UHV-1 NP 
IgY ELISA 
-ve 
23 
(48.94%) 
(67.65%) 
24 
(51.06%) 
(66.67%) 
47 
(100.00%) 
(67.14%) 
2.005 
(1.666 – 2.412) 
3.711 
(2.930 – 4.701) 
2.745 
(2.313 – 3.259) 
4.500 (22) 
(3.819 – 5.181) 
4.750 (24) 
(4.163 – 5.337) 
4.630 (46) 
(3.865 – 5.373) 
UHV-1 NP 
IgY ELISA 
+ve 
11 
(47.83%) 
(32.35%) 
12 
(52.17%) 
(33.33%) 
23 
(100.00%) 
(32.86%) 
2.145 
(1.622 – 2.837) 
4.436 
(3.268 – 6.020) 
3.134 
(2.442 – 4.020) 
4.000 (9) 
(2.562 – 5.438) 
5.083 (12) 
(4.207 – 5.959) 
4.619 (21) 
(3.865 – 5.374) 
 χ2 = 0.076, p=0.930 t = -0.4349, df=32 
p=0.6667 
t = -0.9422, df=34 
p=0.3527 
t = -0.894, df=68 
p=0.3746 
t = 0.773, df=29 
p=0.4458 
t = -0.6797, df=34 
p=0.5013 
t = 0.285, df=65 
p=9774 
UHV-1 NP-C 
IgY ELISA 
-ve 
21 
(47.73%) 
(61.76%) 
23 
(52.27%) 
(63.89%) 
44 
(100.00%) 
(62.86%) 
2.121 
(1.745 – 2.576) 
3.861 
(3.086 – 4.831) 
2.901 
(2.446 – 3.440) 
4.526 (19) 
(3.784 – 5.269) 
4.739 (23) 
(4.265 – 5.213) 
4.643 (42) 
(4.237 – 5.049) 
UHV-1 NP-C 
IgY ELISA 
+ve 
13 
(50.00%) 
(38.24%) 
13 
(50.00%) 
(36.11%) 
26 
(100.00%) 
(37.14%) 
1.938 
(1.508 – 2.492) 
4.079 
(2.870 – 5.798) 
2.812 
(2.186 – 3.618) 
4.083 (12) 
(2.951 – 5.215) 
5.077 (13) 
(3.989 – 6.165) 
4.600 (25) 
(3.846 – 5.354) 
 χ2 = 0.0338, p=0.854 t = 0.6009, df=32 
p=0.5521 
t = -0.2922, df=34 
p=0.7718 
t = 0.2146, df=68 
p=0.831 
t = 0.7342, df=29 
p=0.4687 
t = -0.7021, df=34 
p=0.4874 
t = 0.112, df=35 
p=0.914 
Total 
34 
(48.57%) 
(100.00%) 
36 
(51.43%) 
(100.00%) 
70 
(100.00%) 
(100.00%) 
2.049 
(1.770 – 2.372) 
3.938 
(3.287 – 4.719) 
2.867 
(2.497 – 3.293) 
4.355 (31) 
(3.759 – 4.950) 
4.861 (36) 
(4.395 – 5.327) 
4.626 (67) 
(4.260 – 4.994) 
*Kg, geometric mean , **Mean Years 
 
  
Table 12B. IgM ELISA cut-off point results against population parameters, univariate analysis including stratification by sex 
  
Sex 
(Row%) 
(Col%) 
Weight* 
(95% CI) 
UGV-1: N= 69; UHV- NP, UHV-1 NP-C: N=70 
Age**(n) 
(95% CI) 
UGV-1: N=66; UHV-1 NP, UHV-1 NP-C: N=67 
  M F Total M F Total M F Total 
UGV- 1 
IgM ELISA 
-ve 
14 
(41.18%) 
(41.18%) 
20 
(58.82%) 
(57.14%) 
34 
(100.00%) 
(49.28%) 
2.623 
(2.204 – 3.120) 
3.771 
(2.867 – 4.962) 
3.248 
(2.712 – 3.889) 
5.000 (13) 
(3.983 – 6.017) 
4.750 (20) 
(4.145 – 5.355) 
4.848 (33) 
(4.338 – 5.359) 
UGV-1 
IgM ELISA 
+ve 
20 
(57.14%) 
(58.82%) 
15 
(42.86%) 
(42.86%) 
35 
(100.00%) 
(50.72%) 
1.724 
(1.424 – 2.087) 
3.949 
(3.089 – 5.048) 
2.459 
(2.008 – 3.011) 
3.889 (18) 
(3.167 – 4.610) 
4.867 (15) 
(4.060 – 5.674) 
4.333 (33) 
3.797 – 4.870) 
Total 
34 
(49.28%) 
100.00%) 
35 
(50.72%) 
(100.00%) 
69 
(100.00%) 
(100.00%) 
2.049 
(1.770 – 2.372) 
3.938 
(3.287 – 4.719) 
2.820 
(2.461 – 3.233) 
4.355 (31) 
(3.759 – 4.950) 
4.800 (35) 
(4.338 – 5.262) 
4.595 (66) 
(4.225 – 5.957) 
 χ2 = 1.7590, p=0.185 t = 3.2678, df=32 
p<0.01 
t = -0.2540, df=33 
p=0.818 
t = 2.0827, df=67 
p<0.05 
t = 1.968, df=29 
p=0.0578 
t = -0.2502, df=33 
p=0.8040 
t = 1.417, df=67 
p=0.161 
UHV-1 NP 
IgM ELISA 
-ve 
27 
(50.00%) 
(79.41%) 
27 
(50.00%) 
(75.00%) 
54 
(100.00%) 
(77.14%) 
2.042 
(1.757 – 2.374) 
3.841 
(3.109 – 4.746) 
2.801 
(2.404 – 3.263) 
4.280 (25) 
(3.633 – 4.927) 
4.778 (27) 
(4.237 – 5.319) 
4.538 (52) 
(4.128 – 4.949) 
UHV-1 NP 
IgM ELISA 
+ve 
7 
(43.75%) 
(20.59%) 
9 
(56.25%) 
(25.00%) 
16 
(100.00%) 
(22.86%) 
2.075 
(1.212 – 3.553) 
4.245 
(2.764 – 6.521) 
3.104 
(2.183 – 4.413) 
4.667 (6) 
(2.603 – 6.730) 
5.111 (9) 
(3.994 – 6.228) 
4.629 (15) 
(4.034 
(4.260 – 4.994) 
 χ2 = 0.1930, p=0.660 t = -0.0881, df=32 
p=0.9304 
t = -0.4807, df=34 
p=0.6338 
t = -0.6185, df=68 
p=0.538 
t = -0.5174, df=29 
p=0.6088 
t = -0.6237, df=34 
p=0.5370 
t = -0.893, df=65 
p=0.375 
UHV-1 NP-C 
IgM ELISA 
-ve 
21 
(48.84%) 
(61.76%) 
22 
(51.16%) 
(61.11%) 
43 
(100.00%) 
(61.43%) 
2.155 
(1.812 – 2.564) 
3.754 
(3.003 – 4.602) 
2.863 
(2.436 – 3.364) 
4.350 (20) 
(3.617 – 5.083) 
4.682 (22) 
(4.200 – 5.163) 
4.524 (42) 
(4.109 – 4.938) 
UHV-1 NP-C 
IgM ELISA 
+ve 
13 
(48.15%) 
(38.24%) 
14 
(51.85%) 
(38.89%) 
27 
(100.00%) 
(38.57%)  
1.888 
(1.414 – 2.521) 
4.247 
(3.018 – 5.978) 
2.875 
(2.204 – 3.750) 
4.364 (11) 
(3.152 – 5.576) 
5.143 (14) 
(4.134 – 6.152) 
4.800 (25) 
(4.065 – 4.994) 
 χ2 = 0.0032, p=0.955 t = 0.8911, df=32 
p=0.3795 
t = -0.6709, df=34 
p=0.5068 
t = -0.295, df=68 
p=0.797 
t = -0.022, df=29 
p=0.9826 
t = -0.9792, df=34 
p=0.3344 
t = -0.723, df=65 
p=0.472 
Total 
34 
(48.57%) 
(100.00%) 
36 
(51.43%) 
(100.00%) 
70 
(100.00%) 
(100.00%) 
2.049 
(1.770 – 2.372) 
3.938 
(3.287 – 4.719) 
2.867 
(2.497 – 3.293) 
4.355 (31) 
(3.759 – 4.950) 
4.861 (36) 
(4.395 – 5.327) 
4.626 (67) 
(4.260 – 4.994) 
*Kg, geometric mean , **Mean Years 
 
